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Abstract 
STEM CELL FACTOR AND KIT EXPRESSION IN TYPE I NEUROFIBROMATOSIS 
By Kenneth Eugene Roth, B . S .  
A dissertation submitted i n  partial fulfillment o f  the requirements for the degree o f  Doctor o f  
Philosophy a t  Virginia Commonwealth University 
Virginia Commonwealth University, 1 997 
Director: Thomas F.  Huff, Ph.D. ,  Professor, Department of Microbiology and Immunology 
Neurofibromatosis type I (NF 1) is an inherited disease characterized by the appearance 
of multiple  neurofibromas and an increased incidence of malignant schwannomas, both of 
which contain hyperproliferative Schwann cel ls .  Our laboratory previously reported that 
Schwann cells produce stem cell factor (SCF), a multi potential growth factor known to be  
involved in  mast cell migration and growth. Given the  fact that mast cell numbers are 
increased in both neurofibromas and malignant schwannomas, we set out to evaluate a 
potentia! role for SCF in the development of NFl lesions. First we studied the effects of high 
doses of recombinant SCF on mast cell numbers in vivo, and found that dermal and peritoneal 
mast cell numbers were decreased. Next, we examined the expression of stem cell factor and 
its receptor, Kit, in neurofibromas and malignant schwannoma tumors and cell l ines. 
Using an RNase protection assay, we find that each of four human malignant 
schwannoma cell lines express only the membrane-bound isoform of SCF messenger RNA. 
Xlii 
In contrast, neurofibroma, vestibular schwannoma, and acoustic neuroma tissues, as well as 
the majority of human fibroblast sources, all express the soluble form. Low level expression 
of Kit protein was detected on all four malignant schwannoma cell lines. However, Kit 
expression by Schwann cells was not indicated by immunohistochemical analyses of 
neurofibroma and malignant schwannoma sections, although Kit was readily detected on the 
mast cells within these lesions. We report that bone marrow-derived mouse mast cells appear 
to  be  driven toward a connective tissue phenotype when cultured in the presence of 
conditioned media from Schwann cells of wild type and NFl +/- knockout mice. This effect 
was not observed in cultures containing conditioned medium from Schwann cells of NFl -/­
knockouts .  In addition, the latter appeared to augment the proliferation of mast cells in 
response to exogenous cytokines. 
Together, these results suggest a significant role for stem cell factor and Kit in the 
lesions of NFl. In addition, functional neurofibromin, the product of the NFl gene, may be 
required for proper regulation of SCF isoform expression. The mechanisms by which this 
expression is regulated remain to be clearly defined. 
Introduction 
Type 1 neurofibromatosis (NFl )  is among the most common inherited human diseases, 
affecting one out of3 500 individuals worldwide (Stumpf et aI . ,  1 987) .  The responsible gene 
has been cloned and is located on the long arm of chromosome 17 (Barker et aI . ,  1 987) .  The 
NFl eDNA reveals that the gene encodes a large protein, called neurofibromin, which 
contains a region with homology to mammalian Ras GTPase-activating protein (GAP) and 
the yeast GAP-like proteins IRA I and lRA2 (Xu et aI . ,  1 990). Each of these proteins has 
been shown to inactivate Ras p2 1 ,  the product of the ras protooncogene (Tanaka et aI . ,  
1 990). Ras p21 is activated when i t  i s  bound t o  guanosine triphosphate (GTP), and becomes 
inactive when GTP is converted to guanosine diphosphate (GDP) by its intrinsic GTPase 
activity. GAP and GAP-related proteins induce this activity, thereby serving as negative 
regulators ofRas. It has been reported that the GAP-related domain of neurofibromin indeed 
has GAP-like activity against Ras p2 1 ,  supporting the postulation that neurofibromin 
functions as a tumor suppressor (Weinberg, 1 99 1 ) . 
The clinical manifestations ofNF I are generally associated with the peripheral nervous 
system. Two phenomena which occur at an increased rate of incidence in NF I patients 
involve hyperproliferation of Schwann cells, which are intimately associated with peripheral 
nerves and are normally responsible for the formation of the myelin sheath around them. 
These conditions are termed neurofibromas and malignant schwannomas. The appearance of 
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neurofibromas is a hallmark characteristic of the disease. These are benign peripheral nerve 
tumors consisting primarily of Schwann cells, which account for 60-85% of the cellular 
composition. Fibroblasts make up an additional 1 0-20%, with pericytes, perineurial cells, 
mast cells, endothelial cells and smooth muscle cells also present (Peltonen et aI . ,  1 988) .  It 
has long been known that neurofibroma tissues contain increased numbers of mast cells 
(Isaacson, 1 976; Johnson et aI . ,  1 989), but the mechanism by which this occurs has not been 
well understood. Mast cells can normally be found in perineurial and epineurial spaces of 
peripheral nerves (Bienenstock et aI . ,  1 99 1 ), and are often seen in close proximity to Schwann 
cells (Isaacson, 1 976). In addition, dramatic increases in mast cell numbers are observed in 
situations involving peripheral nerve injury and repair (Isaacson, 1 976) . Neither the means 
by which this occurs, nor a potential role for mast cells in these processes has yet been clearly 
defined. 
The second NF l -related condition involving altered Schwann cell growth is the 
malignant schwannoma, which is also known by other names, including neurofibrosarcoma 
and malignant peripheral nerve sheath tumor. These occur much less frequently than 
neurofibromas, with an incidence of up to 2% in NFl patients (Ponder, 1 990; Nimura, 1 992). 
This is ,  however, a significantly higher rate of occurrence than that seen in genetically normal 
individuals «< 1 %  (Cutler and Gross, 1 93 6)) .  Given the known involvement of Ras p 2 1  in 
the regulation of cellular proliferation, and the evidence that neurofibromin is able to 
functionally regulate the activity of Ras p2 1 ,  i t  seems plausible that the NF I gene defect alone 
could be responsible for these Schwann cell disorders. This, however, does not appear to be 
the case. All patients with NF l appear to have mutations within the same region of 
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chromosome 1 7  (Barker et aI . ,  1 987; Collins et aI . ,  1 988;  Seizinger et aI . ,  1 987), but not all 
have neurofibromas (ponder, 1 990; Riccardi, 1 982) and even fewer develop malignant 
schwannomas, suggesting that additional mutations or other influences are required (Ratner 
et aI. ,  1 990). 
Our laboratory described a soluble factor produced by normal but not Sleel (Sf) 
murine fibroblasts which could promote the growth of mast cells in vitro (Jarboe et aI . ,  1 989) .  
Since then the Sf product, now known as stem cel l  factor (SCF), has been more fully 
characterized in both rodent and human, and is known to exist as either a soluble or 
membrane-bound protein, dependent upon whether the portion of the primary gene transcript 
encoded by exon 6 is included in the final messenger RNA (Flanagan et aI . ,  1 99 1 ) .  The exon 
6-containing mRNA gives rise to a protein that contains a protease-sensitive site in  an 
extracellular membrane-proximal location. This isoform of SCF, after being initially expressed 
as a membrane-inserted protein, is efficiently cleaved by an unidentified protease, releasing 
a biologically active growth factor. Soluble SCF has been described as a potent chemotactic 
agent for cells that express its receptor Kit, the product of the protooncogene c-kil (Blume­
Jensen et aI ., 1 9 9 1 ;  Meininger et aI . ,  1 992)' We recently reported that normal rodent and 
human Schwann cells, and the human malignant schwannoma cell line ST88- l 4, all produce 
SCF (Ryan et al. , 1 994). Interestingly, Hirota and colleagues noted higher levels of stem cell 
factor mRNA in neurofibroma tissue compared with normal skin and suggested that SCF may 
be involved in the increased numbers of mast cells in these lesions (Hirota et aI . ,  1 993)  S ince 
mast cells express the Kit receptor, one might speculate that the mast cel ls in a neurofibroma 
may be recruited to the site by the chemotactic activity of soluble SCF. We have also 
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reported that, although normal rodent and human Schwann cells do not express Kit, the 
ST88 - 14  malignant schwannoma line aberrantly expresses Kit mRNA and protein (Ryan et 
aI. ,  1 994) . These findings have led us to consider whether the abundant growth of Schwann 
cel l s  found in neurofibromas and malignant schwannoma tumors might be due to the 
simultaneous expression of SCF and its receptor by Schwann cells, resulting in an autocrine 
growth loop. In this study, we evaluate Kit expression in three additional human malignant 
schwannoma cell lines and in excised neurofibroma and schwannoma tumors. In addition, we 
determine which isoform of SCF mRNA is produced by these and other sources. 
Literature Review 
Neurofibromatosis type I (NFl) and neurofibromin 
The first full characterization of NF I is generally credited to Friedrich von 
Recklinghausen, who described the disease in 1 882 (von Recklinghausen, 1 882). It i s  for this 
reason that NFl has become known as von Recklinghausen neurofibromatosis, or more 
simply, von Recklinghausen 's  disease. There were, however, some less detailed medical 
descriptions recorded prior to von Recklinghausen ' s account. Two independent reports had 
previously described the disease in multiple family members (Virchow, 1 857 ;  Hitchcock, 
1 862) ,  while the first known descriptions date back to the eighteenth century (Akenside, 
1 785 ;  Tilesius, 1 793 ) .  It was not until early in the twentieth century that neurofibromatosis 
was determined to be a genetic disorder (Thomson, 1 900; Adrian, 1 90 I; Prieser and 
Davenport, 1 9 1 8) .  With a worldwide rate of incidence of about I in 3 500 (Stumpf et aI . ,  
1 987), NFl i s  actually quite a common disease, yet i t  has generally received very little public 
attent ion .  Perhaps the most significant influence promoting public awareness of 
neurofibromatosis has been the incorrect assumption that Joseph Merrick, a grotesquely 
d isfigured man of Victorian England whose life was chronicled in the literary work, The 
Elephant Man (Treves, 1 923), suffered ITom NF I and some of its most serious complications 
(Montague, 1 97 1 ;  Sparks, 1 980). However, after extensive examination of Merrick's remains 
and medical records, it has been suggested that he actual ly did not have NF I, but l ikely 
5 
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suffered from a disease known as the Proteus syndrome (Cohen, 1 988) .  Nonetheless, 
Merrick ' s  life and social struggles have been portrayed in theater, cinema and television, 
bringing widespread attention to neurofibromatosis, albeit through an error in diagnosis. Even 
today some still refer to NFl as, "the Elephant Man ' s  disease."  Interestingly, it has also been 
suggested that Quasimodo, the hunchback in Notre Dame de Paris, was created by playwright 
Victor Hugo based upon his acquaintance with someone who had NF I (Hecht, 1 989;  
Solomon, 1 968). 
Neurofibromatosis type 1 is caused by a mutation in a gene (NFl) which has been 
mapped to the long arm of human chromosome 17 (Barker et aI . ,  1 987), and has since been 
cloned (Cawthon et aI . ,  1 990; Viskochil et aI . ,  1 990; Wallace et aI . ,  1990). It is inherited in 
an autosomal dominant fashion with a penetrance of the mutated gene considered to be very 
nearly 1 00 percent (Riccardi, 1 992). The disease is characterized by the formation of multiple 
cutaneous and subcutaneous neurofibromas, which are benign tumors of the nerve sheath. 
Although these lesions are rarely fatal, they are disfiguring and can be quite painful .  There 
i s  remarkable variability in the number, location and size of the tumors, all of which can 
contribute to the degree of disfigurement and pain. Additional symptoms of NF I include 
localized hyperpigmentation of skin, termed cafe-au-Iait spots, axillary freckling, iris 
hamartomas (Lisch nodules), and sometimes more serious tumors, such as optic gliomas and 
neurofibromas of spinal nerve roots. NF I patients appear to have an increased incidence of 
certain cancers (Riccardi, 1 992; Huson and Hughes, 1 994), particularly malignant 
schwannomas (neurofibrosarcomas), which are generally fatal (Bernards et aI . ,  1 992) .  The 
gene is very large, spanning approximately 3 50  kilobases (kb) of genomic DNA, encoding an 
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mRNA of 1 1  to 1 3  kb, and containing at least 56 exons (Heim et a!. ,  1 994). Sequence 
analysis reveals an open reading frame of28 1 8  amino acids, although alternative splicing may 
encode different protein isoforms (Marchuk et a!. , 1 99 1 ) .  This large protein, called 
neurofibromin, contains a region of360 amino acids which shows significant similarity to the 
catalytic domains of mammalian GTPase activating protein (GAP), as well as to the IRA] and 
IRA2 gene products in yeast, which are inhibitors of the ras proto oncogene product (Xu et 
aI., 1 990). Interestingly, during the course of efforts to characterize the NFl gene, three 
active genes were found embedded within an intron. These genes, OMGP, EVI2B, and 
EVI2A, are transcribed in the opposite orientation from the NFl gene, and encode 
oligodendrocyte-myelin glycoprotein and ecotropic viral integration sites 2B and 2A, 
respectively (Viskochil et a!. , 1 99 1 ) .  
Ras p2 1 (hereafter referred to  simply a s  Ras) i s  the product of  the ra s  protooncogene, 
and can act as a source for either mitogenic or differentiation-inducing signals, depending on 
the cell type (Bar-Sagi and Feramisco, 1985 ;  Hagg et a!. , 1 986;  Noda et a!. , 1 985) .  The 
protein i s  physiologically quiescent when bound to guanosine diphosphate (GDP), and 
becomes activated when the GDP is replaced with guanosine triphosphate (GTP). It returns 
to the inactive state when the GTP is hydrolyzed to GOP by a GTPase activity intrinsic to 
Ras. GAP and other GAP-like proteins inhibit Ras function by stimulating this hydrolysis .  
The GAP-related domain (GRO) ofneurofibromin has been shown to bind Ras proteins avidly 
and to stimulate their GTPase activities (Martin et a!. , 1 990c), suggesting that neurofibromin 
functions as a tumor suppressor (Weinberg, 1 99 1 ) . 
Perhaps due in part to its extensive size, the NFl gene seems to have a predisposition 
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to mutate, with 50% of NFl cases thought to be due to new mutations. Although the GRD 
of neurofibromin has been studied rather extensively, computer searches have revealed little 
similarity between the remainder of sequence and any known proteins in current databases. 
Therefore, the full function ofneurofibromin, and any pathological changes which may occur 
as a consequence ofa mutation at the NFl locus, are not yet well defined. There is  evidence 
that the function ofneurofibromin is not limited to its ability to regulate Ras activity. Johnson 
and coworkers showed by a series of transfection studies that neurofibromin, when 
overexpressed in NIH 3T3 cells, can inhibit cell growth independently of its GAP-l ike activity . 
They also found that melanoma and neuroblastoma cell lines which lack neurofibromin do not 
have increased levels of active Ras (Johnson et aI . ,  1 994) . These findings are consistent with 
later work done by Griesser, et al . which showed that melanocytes cultured from NF I patients 
(from both cafe-au-lait spots and normally pigmented skin) had reduced levels of 
neurofibromin, but still showed similar amounts of GTP-bound Ras when compared to 
melanocytes from healthy donors (Griesser et aI . ,  1 995) .  In a study conducted to determine 
if neurofibromin is involved in melanogenesis, it was found that coexpression of 
neurofibromin in a melanoma cell line caused an increase in expression of a reporter gene 
under the control of the tyrosinase gene promoter (Suzuki et aI . ,  1 994) . Tyrosinase is  a rate­
limiting enzyme in melanin biosynthesis and is expressed only in melanin-producing cel ls .  
These investigators further showed that the GRD of neurofibromin was mainly responsible 
for this induction (Suzuki et aI . ,  1 994) 
Two alternatively spliced isoforms of NFl messenger RNA have been identified and 
tenned type 1 and type 2 (Anderson et aI . ,  1 993; Nishi et aI . ,  1 99 1 ) . The two differ by a 63 
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base pair insertion in the GAP-related domain of the type 2 isoform. Bernards and coworkers 
showed by S I nuclease protection experiments that the two NFl mRNAs are widely 
expressed in human cell lines and tissues, but that the ratio of the two forms differed 
substantially between cell lines (Bernards et a!. ,  1 992) . Gutmann and colleagues have 
reported that type I appears to be associated with cellular proliferation, and that the isoform 
expression switches to predominantly type 2 when the cells undergo differentiation (Gutmann 
et aI . ,  1 993) .  
Until recently, NF I research has been somewhat hampered by the lack of a good 
animal model system. In the 1 980s a naturally occuring disease in the bicolor damselfish 
(Pomacentrus partitus), termed damsel fish neurofibromatosis (DNF), was introduced as a 
possible model for human NFl (Schmale et aI . ,  1 983 ;  Schmale et aI . ,  1 986) These fish 
exhibit multiple neurofibromas and malignant schwannomas, many of which are 
hyperpigmented, indicating similarities to some of the manifestations of human NF I .  
However, while NFl i n  humans is inherited as  an  autosomal dominant mutation, DNF is a 
transmissible disease (Schmale and Hensley, 1 988) .  Nakamura and coworkers induced 
multiple neurofibromas, melanomas, Wilms' tumors, and pheochromocytomas in Syrian 
golden hamsters by transplacental administration of N-Nitroso-N-ethylurea (ENU) and 
considered this as an animal model for human NF I (Nakamura et a!. , 1 989). Perhaps the most 
promising model to date is a strain of mouse recently developed which contains a targeted 
mutation in the NFl gene (Jacks et aI . ,  1 994). Although animals which are heterozygous for 
this mutation (homozygotes die in utero) do not exhibit the classical symptoms of human 
NFl, they do have a high disposition to develop pheochromocytomas and myeloid leukemia, 
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both of which occur with increased frequency in human NF l patients. Surely these models 
will allow for a better understanding of NF l and the symptoms associated with the disease. 
Schwann cells 
Axons in the nervous system are supported, protected, and in some cases myelinated 
by various cell types collectively known as glial cells (from the Greek word for "glue") .  In 
the peripheral nervous system (PNS) the glial cell providing these functions is the Schwann 
cel l .  S chwann cells are derived from the neural crest cells which form during neural tube 
development in embryogenesis (Dupin et aI . ,  1 990; Zimmer and Le Douarin, 1 993) .  As the 
embryo develops, neural crest cells migrate and eventually differentiate into highly specialized 
cell types of neuronal, glial, melanocytic and mesectodermal phenotypes (Le Douarin and 
Dupin, 1 993) .  Fully differentiated neural crest derivatives include Schwann cells, ganglion 
satell ite cells, most of the neurons of the PNS, melanocytes, and part of the cranial 
mesenchyme (Dupin et aI . ,  1 990). During early nervous system development, Schwann cell 
precursors migrate with the developing axons and mUltiply rapidly to accommodate axonal 
growth (Asbury, 1 967; Lemke, 1 990) . Jessen and Mirsky have characterized Schwann cell 
development in the embryonic rat peripheral nervous system according to changes in antigenic 
properties (Jessen and Mirsky, 199 1) . They report that Schwann cell precursors, identifiable 
by embryonic day 1 5 ,  give rise to two morphologically and antigenically distinct mature 
S chwann cell types. These are the myelin-forming cells associated with axons of larger 
diameter, and the non-myelin-forming cells which associate with smaller axons. 
Schwann cell development is dependent upon a close association between Schwann 
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cells and axons. In vivo studies have demonstrated that neurites supply Schwann cells with 
mitogenic signals (Asbury, 1 967; Aguayo et ai , 1 976; Raine, 1 977). These findings were 
supported by in vitro studies which showed that contact with the neuronal surface caused 
S chwann cells to replicate (Salzer and Bunge, 1 980; Ratner et ai , 1 987). The activities 
responsible for this stimulation have been localized to the neuronal cell surface (Salzer and 
Bunge, 1 980; Ratner et ai, 1 988; Mason et ai, 1 989; Wood and Bunge, 1 975; Salzer et ai , 
1 980;  Sobue et ai , 1 983) ,  but no specific mitogenic proteins had been identified until the 
recent characterization of a family of proteins arising from alternative splicing of a single gene. 
These proteins include glial growth factor (GGF, Marchionni et ai. , 1 993), heregulins (HRG, 
Holmes et ai , 1 992), neu differentiation factor (NDF, Wen et ai , 1 992), and acetylcholine 
receptor inducing activity (ARlA, Fal ls  et ai , 1 993) .  GGF has been shown to be a potent 
mitogen for rat Schwann cells (Lemke and Brockes, 1 984). Morrissey and others have 
determined that heregulin i s  involved in the axon-induced mitogenesis of human Schwann 
cells and that the receptor tyrosine kinase p I 85"b02 appears to be the cognate protein on the 
Schwann cell (Morrissey et ai , 1 995; Levi et ai , 1 995) .  
The mitogenic effect ofaxons can be mimicked in vitro by agents which elevate cyclic 
adenosine monophosphate (cAMP), suggesting that axon-associated signals mediate their 
effects by elevating cAMP. In flllther in vitro studies it was found that the cAMP-induced 
progression from a premyelination state to a myelination state required that the cell s  withdraw 
from the cell cycle .  This raises the possibil ity that, in order for a mature Schwann cell to 
begin myelination in vivo, it may require signals which suppress proliferation (Jessen and 
Mirsky, 1 99 1 ) .  Direct cell-cell contact is not an absolute requirement for neurons to regulate 
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all Schwann cell gene expression, however. Using an in vitro co-culture system in which 
primary neurons and adult Schwann cells are separated by a microporous membrane, 
investigators showed that diffusible molecules produced by neurons can repress expression 
of the nerve growth factor receptor p75NGFR in Schwann cells, while inducing expression of 
the myelin protein Po (Bolin and Shooter, 1 993) .  
Under normal circumstances in the ful ly developed organism, the Schwann cell no 
longer undergoes cell division (Peters and Muir, 1 959;  Asbury, 1967) . The intimate axon­
S chwann cell association is retained, and the Schwann cell remains essentially quiescent 
throughout the life of the animal (Asbury, 1 967) unless disrupted by injury or disease, 
resulting in alteration of the normal metabolism of either of the cell types. Under pathological 
conditions such as peripheral nerve injury, demyelination, and tumorigenesis, the Schwann cell 
can be reactivated to enter the cell cycle (DeVries, 1 993) .  The signals required for this 
reactivation are not yet known, although changes in Schwann cell gene expression resulting 
from loss of axonal contact have been described. While neonatal rat Schwann cells grown 
alone in culture express membrane-bound stem cell factor (SCF), those grown in contact with 
dorsal root ganglion (DRG) neurites do not (Ryan et aI . ,  1 994). This raises the possibility that 
loss of axonal contact induces expression of SCF by Schwann cells .  Expression of other 
proteins is induced following loss of axonal contact as a result of nerve damage. These 
include vimentin, neural cell adhesion molecule (N-CAM), glial maturation factor p ,  and nerve 
growth factor receptor IT (NGF-R II). Expression of each of these proteins decreases with 
subsequent nerve regeneration (Jessen et aI . ,  1 987a; Lemke and Chao, 1 988; Taniuchi et a I . ,  
1 988 ;  Bosch et  aI . ,  1 989; Neuberger and Cornbrooks, 1 989;  Mitchell et  aI . ,  1 990). In 
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contrast, loss of axonal contact due to nerve damage causes a decrease in expression of 
myelin-associated glycoprotein, the myelin basic proteins, the Schwann cell myelin-associated 
proteins P2 and Po, and galactocerebroside. Expression of these proteins returns to normal 
levels following nerve regeneration (Jessen et aI, 1 987b; Lemke and Chao, 1 988 ;  Gupta et 
aI . ,  1 990; LeBlanc and Poduslo, 1990; Mitchell et aI, 1 990). 
These examples of Schwann cell gene regulation by axons are likely involved in the 
process by which damaged nerves are repaired . A number of studies suggest that the 
presence of Schwann cells is very impOJ1ant in nerve repair. Following crush injury to the 
optic nerves of rats, regions containing resident Schwann cells were regenerated, whereas no 
regeneration occurred in those areas in which Schwann cells were absent (Berry et aI, I 992a) . 
In addition, when sections of optic nerve were engrafted between the stumps of freshly 
transected sciatic nerves, regeneration only occurred through grafts containing Schwann cells 
(Hall et al . ,  1 992). One possible explanation for this preferential regrowth is that the Schwann 
cells may be able to overcome the inhibitory effects of putative reactive elements within the 
glial microenvironment. Oligodendrocytes and central nervous system (CNS) myelin have 
been implicated in the failure of CNS axons to regenerate after injury (BerlY, 1982; Schwab 
and Thoenen, 1 985;  Caroni and Schwab, 1988), perhaps because of molecules associated with 
both elements which inhibit axonal regrowth (Schwab and Caroni, 1 988) .  It is also suggested 
that Schwann cells contribute to axonal regeneration because they secrete trophic molecules 
(Varon and Williams, 1986), and sequester growing axons within basal lamina tubes (Berry 
et al . ,  1 988;  Hall and Berry, 1 989), possibly isolating growth cones from inhibitory influences 
(Berry et aI , 1 99 1 ,  1 992b). 
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Mitogenic activity can be extracted from neurofibromas (Ratner et aI . ,  1 990), but it 
i s  not clear whether this is important in tumor formation, or whether similar mitogens are 
present in normal peripheral nerves. However, Schwann cells, but not fibroblasts, isolated 
from NFl tumors show angiogenic and invasive properties in the chick chorioallantoic 
membrane (Sheela et aI . ,  1 990) . These effects were not seen when cells from normal human 
peripheral nerves were used, suggesting that neurofibroma Schwann cells secrete one or more 
growth factors that normal Schwann cells do not It is unclear whether Schwann cel ls isolated 
from normal regions of peripheral nerves ofNF I patients display these abnormal angiogenic 
and invasive characteristics. This information would be helpful in determining why tumors 
occur only in limited locations and only in some patients, even though the mutation is 
ubiquitously expressed (Xu et aI . ,  1 990; Wallace et aI . ,  1 990). Either the NFl mutation 
causes all Schwann cel ls to secrete angiogenic activity, or additional mutations or other 
epigenetic changes lead to secretion of this activity only by the tumor cel ls (Eccleston, 1 992). 
The latter possibilities would explain why neurofibromas are restricted to discrete areas. 
Mast cells in neurofibromas 
Mast cell numbers increase in response to nerve damage and repair. This phenomenon 
has been observed in amputation neuromas (Olsson, 1 97 1 ), peripheral nerve injury and 
pathological conditions involving Schwann cells, such as the lesions ofNF I (Isaacson, 1 976) .  
A greater degree of mast cel l  hyperplasia is seen in NFl tumors than in other forms of nerve 
damage (Johnson et aI . ,  1 989). The involvement of mast cells in these lesions continues to 
be a focus of investigation in this laboratory. We have suggested (Roth et aI . ,  submitted for 
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publication) that mast cells or their precursors are perhaps recruited to the site by the 
chemotactic activity of soluble stem cell factor (possibly produced by Schwann cells) . 
Alternatively, they may be trapped there by the binding of Kit on their surfaces to membrane­
associated SCF expressed by the already hyperplastic Schwann cells in the growing lesion .  
Although a clearer understanding of the means by which mast cel ls  accumulate at the s ite of 
a neurofibroma is important, perhaps more so is the potential contribution of mast cel ls to the 
pathogenesis of the tumor itself, or of NF l  in general . Riccardi has hypothesized that mast 
cells accumulate following local trauma (or the elaboration or sequestering of a tropic factor) 
and secrete various substances as usual . Due to an NFl mutation, the response is abnormal, 
resulting in a prol iferation of Schwann cells, fibroblasts, perineurial cells, etc . ,  the 
manifestation of which is a growing neurofibroma (Riccardi, 1 990). Although this is  
speculation at this point, it is not without merit . Mast cells secrete a variety of substances 
with potential mitogenic effects, including heparin and histamine, as well as the well known 
mitogen transforming growth factor-p (Pennington et aI . ,  199 1). Giorno and others have 
demonstrated by transmission electron microscopy that neurofibromas contain, in addition to 
fully granulated mast cells, both partially and fully degranulated cells, indicative of activation 
and mediator release (Giorno et aI . ,  1989). These findings suggest that mast cells are active 
components of neurofibromas rather than mere bystanders. 
Additional evidence of active involvement of mast cells in the symptoms of NFl come 
from clinical observations. Rapidly growing neurofibromas are often accompanied by 
inflammatory reactions such as pruritus and facial flushing (Giorno et aI . ,  1989; Rothe et aI . ,  
1 990) .  The pruritus is not  controlled with standard H I antihistamines such as 
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diphenhydramine hydrochloride (Riccardi, 1 987), but the mast cell stabilizing drugs ketotifen 
and disodium cromoglycate are effective (Riccardi, 1 98 1 ;  Riccardi, 1 987). In some cases, 
treatment with ketotifen even resulted in a decrease in neurofibroma growth (Riccardi, 1 987) .  
The Schwann cells of NFl tumors may also produce substances which exhibit 
mitogenic activities through both autocrine and paracrine mechanisms. Autocrine and 
paracrine growth factors in the supernatant ofNF I neurofibroma cultures have been reported 
which could increase Schwann cell growth in vitro (Riccardi, 1 986) .  Nerve growth factor 
(NGF) is secreted by Schwann cells, especially in the presence of gangliosides (Ohi et a!., 
1 990), and has been shown to induce mast cell proliferation (Matsuda et a!., 1 99 1 )  TGF p  
messenger RNA has been detected in rat Schwann cells, suggesting that TGFp may be 
produced as an autocrine growth factor by Schwann cell tumors (Ridley et a!., 1 989) .  In 
addition, a schwannoma-derived growth factor (SDGF) has been isolated which has homology 
to epidermal growth factor (EGF) and glial growth factor (GGF), and which can stimulate 
proliferation of Schwann cells, fibroblasts and astrocytes (Kimura et a!., 1 990). In light of the 
current evidence, it seems possible that Schwann cell-mast cell interactions are important in 
the maintenance of both populations within a neurofibroma, and may make significant 
contributions to tumorigenesis. 
Mast cell overview 
It is interesting that the first detailed description ofNF I was reported by Friedrich von 
Recklinghausen, as mentioned above (von Recklinghallsen, 1 882), because he also may well 
have been the first to describe mast cells when he recorded his observations of granular cells 
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in unstained preparations of frog mesentery (von Recklinghausen, 1863). The actual credit 
for establishing that mast cells were a distinct lineage, however, goes to Paul Ehrlich. He 
found that granules within cells obtained from frog mesentery exhibited metachromatic 
staining with aniline dyes (Ehrlich, 1878). The name he gave these cells, "mastzellen," is 
derived from the German word "masten," which means "feed or fatten," because Ehrlich 
believed that the intracellular granules were the result of ingestion of particles, or over­
feeding. Ehrlich also noted that mast cells had a tendency to localize around blood vessels 
and nerves, and in areas of inflammation or neoplasia. 
Over the years, theories concerning the origin and lineage relationships of mast cells 
have evolved along with advances in scientific investigation At first some thought that mast 
cells arose from lymphocytes, fibroblasts or macrophages (Valent et aI. , 1989; Burnet, 1977; 
Zucker-Franklin et aI., 1981; Czarnetzki et aI., 1982). Others believed they were derived from 
mesenchymal cells, plasma cells, histiocytes, endothelial cells, or degenerate cells (reviewed 
in Michels, 1963). The current theory is that mast cells arise from hematopoietic stem cells 
in the bone marrow. Kitamura and colleagues demonstrated this using adoptive transfer 
experiments involving the mast cell-deficient W/W' and Sl/Sr mice. They found that they 
could cure the mast cell deficiency in W/w' mice by injecting them with bone marrow from 
congenic normal littermates or from Sf/Sf' mice (Kitamura et aI., 1978). Others observed that 
mast cells could be grown in vitro from bone marrow when cultured in the presence of a 
variety of cell culture-conditioned media now known to contain interleukin 3 (IL-3), a growth 
factor for murine mast cells (Hasthorpe, 1980; Nabel et aI., 1981; Razin et aI. , 1981; Schrader 
et al., 1981; Tertian et aI., 1981;Yung et al., 1981). Both in vitro (Kirshenbaum et al , 1991; 
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McCarthy et aI., 1980) and in vivo (Fodinger et aI., 1994) studies have suggested that human 
mast cells also originate in the bone marrow. Mast cells in the human are now known to arise 
from CD34+ hematopoietic progenitors, but not from CD34- bone marrow cells (Kirshenbaum 
et aI. , 1991). 
Although it is generally accepted that mast cells originate in the bone marrow, their 
relationship to other hematopoietic lineages is still unclear. Mast cells were long thought to 
have arisen from the same progenitor as the basophil, because both have granules which 
exhibit metachromatic staining, both contain histamine, and both express the high affinity 
receptor for IgE (FccRI). Similarities between the two cell types have been observed at the 
ultrastructural level as well (Zucker-Franklin, 1980). This common progenitor theory has 
become less popular, however, as the current body of knowledge has grown. Mast cells and 
basophils differ in nuclear morphology, granule content, location in the organism, and 
response to external stimuli (reviewed in Galli and Lichtenstein, 1988; Valent and Bettelheim, 
1 990) . Also, mast cells leave the bone marrow as immature progenitors, completing their 
differentiation in the peripheral tissues, while basophils are not released until they are fully 
mature, terminally differentiated cells (McNeil, 1996). The fact that mast cells express the 
transcription factors GAT A- I ,  GAT A-2 and GATA-3 (Martin et aI , 1990a; Zon et aI., 1991) 
is another point which distinguishes them from the basophil lineage. Rather, these findings 
suggest that mast cells may share a common progenitor with erythrocytes and 
megakaryocytes, which also express the GAT A binding proteins. 
A possible relationship between mast cells and the monocyte/macrophage lineage has 
also been suggested based upon the observation that human mast cells are recognized by some 
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monoclonal antibodies specific for differentiated macrophages (Valent et aI., 1989). Also, 
both cell types differentiate in the periphery, and both activated macrophages and activated 
mast cells produce cytokines (reviewed in Costa et aI., 1993; Galli et aI., 1991; Galli et aI . ,  
1 993 ; Gordon et aI., 1990; Paul e t  aI., 1993). However, Agis and others have found that 
human mast cells are not derived from monocytes cultured in the presence of stem cell factor, 
and suggest that the mast cell does not arise from a monocyte/macrophage precursor (Agis 
et aI., 1993). This group went on to show that mast cells developed from a peripheral blood 
progenitor which was CD34+, Kit+, Ly" ,  CD 14" ,  and CD I T .  These data indicate that mast 
cells do not appear to originate from circulating monocytes (CD 14+), basophils (CD I r), or 
lymphocytes (Ll), but demonstrate that mast cells are replenished directly from early 
hematopoietic progenitors and therefore represent a unique hematopoietic cell lineage (Agis 
et aI., 1 993). In spite of the advances being made in the field of mast cell biology, a specific 
relationship of the mast cell to other hematopoietic lineages continues to be debated. 
There is considerable structural and functional heterogeneity within the mast cell 
lineage in both the human and rodent. Mast cells found in human lung and intestinal mucosa 
were shown by electron microscopy to contain granules with many scroll-like crystal 
structures, (Craig et aI., 1988; Weidner and Austen, 1 990). These granules contain a subclass 
of tryptic serine proteases (tryptases), leading to the classification of these cell s  as MCT, for 
"mast cell/tryptase" (Irani et aI., 1986). A second subset of mast cells is found in the 
connective tissue stroma of skin, intestinal submucosa, breast parenchyma and lymph nodes, 
and interacts with microvascular and neural networks. Electron miscroscopy of these cells 
reveal very few scroll-like structures (Craig et aI. ,  1988; Weidner and Austen, 1990), and they 
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have been named MCTO because their granules contain both tryptases and chymases, as well 
as an exopeptidase, carboxypeptidase A (Irani et a!. ,  1986). The two subsets of human mast 
cells also exhibit functional differences. For instance, Mere are responsive to the complement 
component CSa, morphine derivatives, and various neuropeptides, but MCT are not sensitive 
to these stimuli (Cohan et a!. ,  J 989). 
Two subsets of mast cells in rats and mice have been characterized based upon tissue 
localization, T cell-derived growth factor dependence, and protease expression. The 
connective tissue mast cell (CTMC) and the mucosal mast cell (MMC) in rodents are in many 
ways comparable to the MCTe and the M�. of the human, respectively. The CTMC and 
MMC in the mouse can be distinguished by their differential expression of a large family of 
serine proteases (McNeil and Austen, 1 994). Jarboe and colleagues have identified two types 
of murine mast cell progenitors: one that is dependent upon interleukin-3 (IL-3), and another 
that is not, but instead responds to a fibroblast-derived factor (Jarboe and Huff, 1989; Jarboe 
et a!., J 989). These two progenitors may give rise to MMC and CTMC, respectively 
(Kobayashi et a!., 1986). There is evidence, however, that murine mast cells can change their 
phenotypic characteristics in response to alterations in their microenvironment (McNeil and 
Austen, 1994; Ghildyal et a!. ,  1992; Gurish et a!., 1 992). Mast cells which appear to be 
morphologically differentiated are long-lived, can proliferate extensively, and are able to 
change their phenotype (Takagi et a! . ,  1992). It may be that this ability to change phenotype 
in response to environmental stimuli enables murine mast cells to adapt their functional 
capabilities in response to diseases or immunologic responses. In the human system, however, 
the ability of mast cells to switch from one phenotypic subset to the other has not been 
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demonstrated. Some investigators have suggested that human mast cells may commit to 
either the MCT or the M�c subset early and proceed upon distinct pathways (Irani et aI., 
1992; Craig et aI., 1989) 
It seems that the bulk of our understanding would implicate the mast cell as an "evil ­
doer" which presents itself as  a mere nuisance, as  in  those who suffer milder forms of  al lergy, 
or as a serious threat, as in the case of victims of anaphylaxis. The mast cell' s  involvement 
in type I hypersensitivity, allergic asthma and numerous intlammatOlY processes is widely 
accepted (reviewed in McNeil, 1996; Galli and Costa, 1995). Moreover, there is significant 
evidence that mast cells are involved in sudden infant death syndrome (Platt et aI . ,  1 994). 
Although logic dictates that the mast cel l ' s  evolutionary persistence implies an essential 
function in normal physiology, our inability to assign functions to the mast cell that are 
beneficial to the organism underlies the "riddle of the mast cel l" (McNeil, 1 996; Galli, 1990). 
Kit, the product oj the c-kit protooncogene 
In the course of maintaining inbred strains of mice for use in research, scientists are 
sometimes given the 0PPoliunity to study the functions of unidentified gene products which 
have been altered in some way due to spontaneous mutations in these strains. These 
"experiments of nature" have been extremely important in our understanding of the functions 
of stem cell factor (SCF) and its receptor, Kit. Much of what we now know about the 
involvement of SCF and Kit in hematopoiesis and developmental programs involving 
melanocytes, genn cells and mast cells was predicted based on studies with mutant mice long 
before the gene products were identified. 
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For a number of years it has been known that mutations at either the dominant white 
spotting (W) locus on chromosome 5 or the steel (Sf) locus on chromosome 1 0  resulted in 
similar phenotypic changes. These include changes in coat pigmentation, severe macrocytic 
anemia, sterility, and a dramatic reduction in the number of mast cells (Kitamura et aI., 1 978; 
Kitamura and Go, 1 979; Russell, 1 979; Silvers, 1 979). Following transplantation and embryo 
fusion studies using W and Sf mutant mice and in vitro studies using cells and tissues from 
them, it was suggested that deficits in the W mutant mice were expressed by the cells in the 
affected lineages, and those in the Sf mutants were expressed by cells in the microenvironment 
necessary for the development of the affected lineages (Russell, 1 979; Silvers, 1 979). The 
similarities of phenotypic changes resulting from mutations at either locus suggested that the 
W locus might encode a receptor expressed by the cells of the affected lineages, while the Sf 
locus might encode the cognate ligand (Russell, 1 979). More recent work has confirmed that 
the W locus is allelic with the c-kit gene, which encodes a receptor tyrosine kinase (Chabot 
et aI. , 1 988; Geissler et aI., 1 988a, b), and that SI encodes the corresponding ligand, which 
has been given several names, including stem cell factor (SCF, Zsebo et aI., 1 990a, b; Martin 
et al. ,  1 990b), Kit ligand (KL, Huang et aI., 1 990), mast cell growth factor (MGF, Williams 
et al. ,  1 990; Copeland et aI., 1 990; Anderson et aI., 1 990), and steel factor (SLF or SF, Witte, 
1 990; Williams et aI., 1 992a). 
The kit gene was first characterized as the viral oncogene v-kit of a feline sarcoma 
virus (Besmer et aI . ,  1 986). It was later determined that v-kit arose from transduction and 
truncation of the cellular protooncogene c-kit (Yard en et aI., 1 987; Qiu et aI., 1 988). The c­
kit gene was first cloned in the mouse from a brain cDNA library (Qiu et aI, 1 988). The 
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predicted amino acid sequence was found to  display significant homology to  members o f  a 
family of transmembrane receptors now known as type III receptor tyrosine kinases (RTKs), 
which includes the receptor for macrophage colony stimulating factor (MCSF, encoded by 
c-fms), the platelet-derived growth factor (PDGF) receptors alpha and beta (Besmer et a!. ,  
1 986;  Varden e t  a!., 1987; Qiu e t  a!. ,  1988), and the more recently described receptor 
Flk2/Flt3 (Lyman et a!., 1993). 
The Kit protein contains an extracellular ligand-binding domain with five 
immunoglobulin-like regions. These regions contain several intramolecular disulfide bonds 
and potential N-glycosylation sites (Yarden et a!. ,  1987; Qiu et a!., 1988) The intracellular 
portion of the protein contains a kinase region which is split into two parts by a noncatalytic 
stretch of 77 amino acids known as the kinase insert (Yarden et a!., 1987; Qiu et a!., 1988). 
It has been demonstrated in the murine system that a specific tyrosine residue within the 
kinase insert (Y719) is critical for signal transduction through physical association with 
phosphatidylinositol 3 ' -kinase (PI3K), and that Y719 must be phosphorylated before this 
association can occur (Serve et a!., 1994). 
Upon binding to stem cell factor, Kit is induced to dimerize, and this dimerization 
correlates with autophosphorylation and activation of its kinase (Blume-Jensen et a!., 1991; 
Philo et a1., 1 996). After activation, Kit rapidly associates with specific cytoplasmic signaling 
proteins involved in cell proliferation and survival, including PI3K and phospholipase C-y 1 
(PLCyl) (Rouapel et a!., 1991). In contrast to the loss of Kit function observed in the 
various W mutant mice, some activating mutations have been reported in both mouse and 
human. The factor-independent tumorigenic murine mastocytoma cell line P8 1 S  was found 
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to express a constitutively tyrosine-phosphorylated Kit receptor, in the absence of endogenous 
or exogenous SCF (Rottapel et a!., 1991). Furitsu and coworkers discovered that the Kit 
protein in the human mast cell leukemia cell line HMC- l was also constitutively 
phosphorylated in the absence of SCF. In addition, they found two point mutations in the 
region encoding the cytoplasmic domain of the receptor (Furitsu et a!., 1 993). These findings 
are suggestive that some activating c-kit mutations may contribute to transformation of some 
cells. Nagata et a!. have identified a point mutation in the catalytic domain of Kit in patients 
who have mastocytosis with an associated hematologic disorder. Identical or similar amino 
acid substitutions in mast cell lines resulted in ligand-independent autophosphorylation of the 
receptor (Nagata et a!., 1995). 
In addition to activating mutations of the receptor, aberrant signal transduction 
through Kit may result from autocrine stimulation arising either from ectopic expression of 
Kit in tissues that normally express SCF, or from ectopic expression of SCF in tissues that 
normally express Kit. Indeed, coexpression of the receptor and ligand has been reported in 
gynecological tumors (Inoue et a!., 1994), colon tumor cell lines (Toyota et a!., 1 993), in the 
majority of surgical breast tumor specimens and tumor cell lines (Hines et a!., 1995), and in 
at least 70% of small cell lung carcinoma (SCLC) tumors and tumor-derived cell lines (Hibi 
et aJ . ,  1 99 1 ). Moreover, Krystal et al. showed that transfection of a c-kit expression vector 
into an SCLC line that expressed SCF but not Kit resulted in constitutive tyrosine 
phosphorylation of immunoprecipitated Kit protein and more vigorous cell growth in serum­
free medium compared to control-transfected cells. This group also reported that transfection 
of an SCLC line which normally coexpresses SCF and Kit with a dominant negative, kinase-
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defective c-kit gene resulted in  a significant loss of growth factor independence (Krystal e t  aI . ,  
1 996) 
The phenotype of the W and SI mutant mice suggest that SCF and Kit are likely 
involved in development of hematopoietic, melanoblast, and germ cell lineages in the 
developing mouse embryo. Studies examining the patterns of expression of the two proteins 
have confirmed this involvement in terms of the migration and spatial distribution, as well as 
the proliferation and differentiation of the cells at their definitive sites in the developing 
embryo (Matsui et aI., 1990; Orr-Urtregger et aI., 1990; Keshet et aI., 1991). However, 
expression was also detected in tissues other than those apparently affected in the W and SI 
mutants. These findings have indicated a possible role for Kit signaling in the development 
of cells in the placenta, the nervous system, the septa of the heart, the lung, the facial 
chondrogenic nuclei, and the midgestational kidney (Galli et aI . ,  1 994) Clearly, SCF and Kit 
are of vital importance in the early development of the animal. In fact, loss of function 
mutations in both alleles of either locus leads to an inability to properly develop, resulting in 
the death of the fetus in utero (Nocka et aI , 1 989) 
Stem eellfactor 
After it had been established that the W locus of the mouse was allelic with c-kil, it 
was reasonable to imagine that the ligand might be encoded at SI, in accord with Russell' s  
earlier proposal (Russell, 1979). Experiments using combinations o f  mast cells or  their 
precursors and fibroblasts derived from W or SI mutant mice provided strong biological 
evidence that fibroblasts can produce membrane-bound (Kitamura et aI , 1 989; Fujita et aI . ,  
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1989; Kitamura and Fujita, 1989) and soluble (Jarboe and Huff, 1989) forms of the Kit ligand. 
Soon after these reports, Nocka et al. purified and characterized a mouse fibroblast-derived 
factor which could stimulate growth of normal mast cells, but not mast cells derived from W 
mutant mice (Nocka et aI., 1990). Later that year three groups simultaneously reported the 
cloning and characterization of the growth factor (designated SCF in this review) which 
represented the product of the Sf locus, and a ligand for the receptor encoded at c-kit 
(Williams et aI., 1990; Copeland et aI., 1990; Anderson et aI., 1990; Zsebo et aI., 1990a, b; 
Martin et aI., 1990b; Huang et aI., 1990). 
Physical characterization of the SCF protein indicates that it is heavily glycosylated, 
and exists as noncovalently associated dimers (Arakawa et aI., 1 991; Lu et aI. , 1991; Langley 
et a1 . ,  1992). In the human, alternative splicing of the mRN A gives rise to two forms of SCF 
protein: soluble or membrane-bound (Anderson et aI., 1991). The full-length mRNA encodes 
a transmembrane protein of 248 amino acids, which includes a 25 amino acid cleaved signal 
peptide, a 189 amino acid extracellular domain, which includes a membrane-proximal 
proteolytic cleavage site encoded by exon 6, a hydrophobic membrane-spanning region of 2 1 -
23 amino acids, and a short intracellular domain of 36-37 amino acids. This form i s  efficiently 
cleaved by an unidentified protease and released as soluble SCF Exon 6 is not included in 
the alternative SCF mRNA, which encodes a transmembrane protein that lacks 28 amino 
acids, including those which comprise the protease recognition site (Anderson et aI., 1991). 
This form is much more resistant to proteolysis and generally remains associated with the cell 
membrane. Three isofonns of SCF have been reported in the mouse, including exon 6-
containing and exon 6-lacking forms similar to those found in the human, and a third form 
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which contains a smaller 16 amino acid deletion of the exon 6 sequence. This deletion also 
eliminates the protease recognition site, giving rise to a predominantly membrane-bound 
protein (Anderson et aI., 1 990; Flanagan et aI . , 1 991). The transcriptional and post­
translational events necessary for production of either soluble or membrane-bound SCF are 
obvious points at which a given cell may regulate SCF isoform expression. The biological 
effects of membrane-bound vs. soluble SCF may be significantly different (see later 
discussion), as has been reported with respect to bone marrow progenitor cells (Toksoz et aI., 
1 992). 
Although most functional studies of SCF have focused on the biological activities of 
the extracellular portions of the proteins (soluble or membrane-bound), there is limited 
evidence that the short cytoplasmic tail may have biological importance which has not yet 
been defined. This is suggested by the phenotype of mice bearing a mutation designated SI' 1H, 
which produces a splicing defect resulting in a cytoplasmic tail of 28 amino acids, rather than 
36 .  The phenotype of SI'7J '/SI'1H mice includes sterility in males but not in females, indicating 
that some biological activity resides in the cytoplasmic tail of SCF (Brannan et aI., 1992). 
SCF expression appears to be tightly regulated during mouse embryogenesis. 
Examination of the genital ridges of 10-day embryos revealed a gradient of SCF expression 
along the route of migration of primordial germ cells between the dorsal mesentery and the 
gonad anlage. Interestingly, an inverse gradient of c-kit expression was observed, with SCF 
expression highest in the genital ridge and c-kit expression highest in the dorsal mesentery. 
By day 1 1 . 5 ,  when colonization of the gonad is completed and germ cell migration is no 
longer necessary, SCF expression along the migratoIY route ceases, but remains high in the 
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gonad throughout sexual differentiation (Matsui et  aI . ,  1 990; Orr-Urtregger et  aI., 1 990; 
Keshet et aI . ,  1 991). 
In the ovary of the adult mouse, c-kit is expressed only by the oocytes (Arceci et aI., 
1 992; Orr-Urtregger et aI . ,  1 990; Keshet et aI., 199 1 )  and SCF is expressed at highest levels 
in the surrounding granulosa cells (Keshet et aI., 1 99 1 ) . The observed pattern of SCF 
expression during sexual development supports the hypotheses of several groups that cells 
lining the migratory route may guide the primordial germ cells by way of haptotaxis through 
expression of membrane-bound SCF, whereas expression of SCF in the gonad anlage may 
indicate a chemotactic role for soluble SCF in directing homing of germ cell precursors 
(Flanagan and Leder, 1 990; Williams et aI . , 1 990; Matsui et aI., 1990; Flanagan et aI . ,  1 99 1 ;  
Keshet e t  aI., 1 99 1 ). Similar haptotactic/chemotactic roles for SCF in the development of 
pigmentation have been suggested by studies of SCF and c-kit expression during melanocyte 
migration (Keshet et aI., 1991 ). SCF expression can be detected in the subdermal 
mesenchymal cells of the limb buds before melanocytes begin to invade, and persists during 
and after melanocyte colonization. c-kit is detected in the melanocyte precursors and remains 
throughout their proliferation and differentiation (Keshet et aI., 1991). 
SCF and c-kit also appear to be important in the early development of the brain . 
Between gestational days 1 2  and 1 5, SCF is expressed in the floor plate of the neural tube, 
followed by expression in the ventrolateral regions associated with motor neuron 
differentiation (Matsui et aI., 1990; Orr-Urtregger et aI., 1990). c-kit expression has been 
detected in migrating neural crest cells and in the differentiating neurons in the dorsal neural 
tube and dorsal ganglia, suggesting that SCF may function as a chemoattractant for neurons 
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and/or axonic processes (Keshet et a!., 1991). 
Expression of c-kit is high in the embryonic liver at gestational day 1 1 . 5 ,  a time at 
which the liver is heavily involved in hematopoiesis (Orr-Urtregger et a!., 1990; Keshet et a!., 
1 99 1 ), consistent with the widely accepted view that SCF is an important hematopoietic 
growth factor. In the adult mouse hematopoietic system, c-kit mRNA expression is found 
predominantly in those lineages affected by W mutations, including mast cells and early 
erythroid and myeloid cell lines (Andre et a! . ,  1989; Nocka et a! . ,  1989) Using '2 SI-labeled 
SCF in binding studies, Metcalf and Nicola found that Kit is widely distributed among cells 
in adult murine bone marrow. They rep0I1ed expression on blasts, promyelocytes/myelocytes, 
promonocytes, monocytes, eosinophilic myelocytes, eosinophils, and some lymphocytes 
(Metcalf and Nicola, 1991). In general, analysis of the distribution of c-kif mRNA and Kit 
protein on hematopoietic cells indicates that levels of Kit are highest during early stages of 
development and progressively diminish in parallel with maturation of the various 
hematopoietic lineages (Papayannopoulou et a!., 1991). The mast cell represents an 
exception, in that mature mast cells continue to express the receptor and exhibit 
responsiveness to SCF. 
The biological consequences of SCF/Kit interactions include adhesion, chemotaxis or 
haptotaxis, survival, proliferation, differentiation, and activation or modulation of secretion 
(reviewed in Galli et a!., 1994). The various functions would require that the expression of 
the appropriate isoform of SCF be specifically regulated, although the mechanism of this 
regulation is presently unknown. The membrane-bound form would understandably be 
involved in adhesion to Kit-bearing cells. Studies using cells expressing the sri allele, which 
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makes only soluble SCF, have demonstrated that a membrane-associated form of SCF is 
necessary for adhesion to mast cells (Flanagan et aI. ,  1991; Kaneko et aI., 1991; Adachi et aI . ,  
1 992) .  Conversely, Adachi and coworkers have shown that mast cells derived from WIW 
mice, which express no Kit on their surface, were greatly impaired in their ability to bind to 
fibroblasts (Adachi et aI . ,  1992). The same group demonstrated that Kit tyrosine kinase 
activity was not necessary for adhesion to fibroblasts by using mast cells derived from W"I W" 
or WIW'2 mutants, which bear Kit receptors with greatly diminished or completely absent 
kinase activity, respectively (Adachi et aI., 1992). As mentioned above, it has been suggested 
that membrane-bound SCF may promote attachment of mouse primordial germ cells during 
embryonic development (Matsui et aI., 1991). It has also been shown that neutralizing 
antibodies to Kit can inhibit the binding of human megakaryocytes to fibroblasts (Avraham 
et aI., 1 992). These studies offer strong evidence that SCF and Kit can function as adhesion 
molecules. 
The defects in coat pigmentation, mast cell deficiency, and sterility characteristic of 
W and SI mutant mice are known to reflect an impairment of the migration of cells of the 
melanocyte, mast cell, or germ cell lineage during embryonic development (Russell, 1979; 
Silvers, 1 979; Kitamura, 1989). Upon identification of the proteins encoded at these loci, it 
was reasonable to assume that this migration may be due to a chemotactic response of the Kit­
bearing cells to SCF. It has been shown that subcutaneous injections of recombinant SCF into 
the skin of SI/Sf mice, which ordinarily lacks mast cell precursors and mature mast cells 
(Kitamura and Go, 1979; Hayashi et aI. , 1985), resulted in the appearance of large numbers 
of mast cells at the site of injection (Zsebo et aI., 1990b; Tsai et aI. , 1991). In vitro studies 
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have demonstrated that porcine aortic endothelial cells transfected with wild-type human c-kit 
cDNA exhibited chemotactic responses to concentrations of recombinant human SCF as low 
as 50 pg/mJ (Blume-Jensen et aI., 1991). It was further shown that Kit tyrosine kinase activity 
was necessary for chemotactic responsiveness to SCF (Meininger et aI., 1992). 
Given the fact that certain Kit-expressing cells, such as oocytes, melanocytes, and 
mast cells are able to reside in the tissues for long periods of time without undergoing 
proliferation, one might imagine that SCF is involved in promoting their survival. There are 
several lines of evidence that support this theory, and that suggest that the membrane­
associated form of SCF is responsible. When normal mast cells were injected into the dermis 
of Sf/Sf mice, which lack membrane-bound SCF, they did not survive (Gordon and Galli, 
1 990). However, the mast cells did survive when injected into the skin of W'/W" mice, 
suggesting that membrane-bound SCF is necessary for, or at the least, more effective than 
soluble SCF for promoting the survival of mast cells (Gordon and Galli, 1 990) Toksoz et al. 
demonstrated that the membrane-bound form of SCF maintained hematopoiesis for longer 
periods than the soluble form (Toksoz et aI., 1992). Although membrane-bound SCF is better 
at maintaining the survival of mouse primordial germ cells in vitro (Dolci et aI., 1991; Matsui 
et aI., 1 991), it has been shown that soluble SCF can also maintain the survival of mouse 
primordial germ cells (Dolci et aI., 1991; Godin et aI , 1 991; Matsui et aI , 1991), 
hematopoietic stem cells (Bernstein et aI , 1991; McNiece et aI , 1991; Metcalf and Nicola, 
1991 ;  Tsuji et a1., 1991; Cicuttini et aI., 1992; Migliaccio et aI, 1992; Williams et aI., 1992b), 
human melanocytes (Funasaka et aI., 1992), human mast cells (Irani et aI., 1992; Valent et aI , 
1 992; Mitsui et aI, 1993), or human NK cell precursors (Uittenbogaart et aI, 1992) in vitro, 
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and can promote the survival o f  mouse mast cells in vitro o r  i n  vivo (Zsebo et aI . ,  1 990b; Tsai 
et aI.,  1 99 1 ) .  In addition, Iemura and others have provided evidence that SCF promotes the 
survival of mast cells by suppressing apoptosis (lemura et aI . ,  1 994) . 
An in vitro mast cell proliferation assay has been the standard bioassay for 
characterizing SCF bioactivity since the cloning of the gene (Will iams et aI . ,  1 990; Copeland 
et aI . ,  1 990; Anderson et aI . ,  1 990; Zsebo et aI . ,  1 990a, b;  Martin et aI . ,  1 990b; Huang et aI . ,  
1 990). There can b e  little argument about the ability o f  SCF t o  induce proliferation i n  mast 
cells. However, the effects of SCF on the proliferation of other Kit-bearing lineages is most 
dramatic in the context of synergism with other stimuli (reviewed in Galli et aI . ,  1 994) . SCF 
is  much more effective in inducing proliferation of cultured mouse primordial germ cel ls  when 
leukemia inhibitory factor (UF) is added as a cofactor (Matsui et aI . ,  1 99 1 ) . Human 
melanocytes proliferate ill vitro when SCF is provided with PMA, but SCF alone has little 
effect (Funasaka et aI . ,  1 992) . Similarly, SCF by itself has only modest effects on the 
development of colonies of hematopoietic cel ls  ill vitro, but acts in synergy with many other 
growth factors to promote the production in vitro of early and intermediate precursors of 
erythroid, myeloid, and lymphoid lineages (Galli et aI . ,  1 994). 
Finally, SCF can function as an agent to stimulate mediator release from mast cells 
through Kit signaling. SCF-induced mediator release has been demonstrated in purified 
human skin mast cells (Columbo et aI . ,  1 992) and from purified mouse peritoneal mast cells 
(Coleman et aI . ,  1 993) in vitro. In addition, ill vitro studies with human lung (Bischoff and 
Dahinden, 1 992) or skin (Columbo et aI . ,  1 992) mast cells or with purified mouse peritoneal 
mast cells (Coleman et aI . ,  1 993) also showed that soluble SCF can enhance the level of mast 
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cell secretion and mediator release observed i n  cells stimulated through the high affinity IgE 
receptor (FcERI). This effect was seen at SCF concentrations substantially lower than those 
required to induce mediator release directly. Taken together, these data indicate that SCF i s  
involved in mast cell development and function. It is not clear to what extent SCF may also 
influence the functional activity of other lineages that express Kit. 
Materials and Methods 
Animals 
Female BALBlc mice, 8- 1 0  weeks of age, were purchased from the National Cancer 
Institute, Frederick, MD . They were maintained in laminar flow housing and provided with 
food and water ad libitum. 
Antibodies 
An affinity-purified rabbit IgG polyclonal anti-human c-kil antibody raised against a 
synthetic peptide (American Research Products, Inc. ,  Belmont, MA) was the primary antibody 
used for immunohistochemistry. Control experiments were performed using rabbit IgG 
purified from serum of non-immunized animals (Jackson Immunoresearch Laboratories, Inc . ,  
West Grove, PA).  Immunofluorescent staining was done with a monoclonal anti-human c-kil 
antibody (clone l .D9.3D6, Boehringer Mannheim Biochemica, Indianapolis, IN) Non­
specific interactions were blocked with a solution containing purified human IgG (Jackson) . 
A mouse IgGJ (Biosource International, Camarillo, CA) was used as a negative contro l .  In 
the immunofluorescence studies, anti-c-kit antibodies were localized using a biotin-conjugated 
F(ab')2 goat anti-mouse IgG (Jackson), followed by fluorescein isothiocyanate (FlTC)-labeled 
streptavidin (Pierce, Rockford, IL) . 
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Cells and eell lines 
The murine fibroblast cell line BALBlc 3T3, the human fibroblast lines CCD 1 8, HS68 
and MRC-9, and the human fibrosarcoma cell line HT 1 080 were a l l  obtained from American 
Type Culture Collection, Rockville, MD . The four human malignant schwannoma cell lines 
were generous gifts of Dr. George DeVries, Department of Cell Biology, Neurobiology and 
Anatomy, Loyola University, Chicago, IL. The ST88- 1 4  line was derived from a peripheral 
nerve sheath tumor of a patient diagnosed with NF I (Fletcher et aI, 1 99 1 ) , and partially 
described elsewhere (DeClue et aI , 1 992; Reynolds et aI , 1 992). Due to contamination of 
this line, a separate clone was obtained directly from Dr. Jonathan Fletcher, Department of 
Pathology, Brigham and Women's Hospital, Boston, MA. Other malignant schwannoma cell 
lines include the STS-26T line, which was derived from an isolated grade III malignant 
schwannoma in a patient who did not have NF l (Dahlberg et aI , 1 993), the NF- I T cell line, 
derived from a malignant soft tissue sarcoma in an NF l patient (Dahlberg et aI , 1 993), and 
the T265-2c cell line, which was established in the laboratory of Dr. George DeVries from a 
malignant schwannoma in a patient with NF I .  The HMC- I cell line was derived from a 
patient with mast cell leukemia, and was the kind gift of Dr. Joseph H. Butterfield, M .D . ,  
Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, MN. Al l  cells except HMC-
1 were maintained in Dulbecco' s  modified Eagle ' s  medium supplemented with 2mM L­
glutamine, 50/-lg/ml gentamicin, 1 00U/ml penicillin, 1 00/-Ig/ml streptomycin, and 1 0% fetal 
calf serum (cDMEM) in a humidified chamber at 3 r C  and 5% CO2 . HMC- I cells were 
grown in Iscove's modified Dulbecco' s  medium with 1 0% defined, iron-supplemented bovine 
calf serum (Hyclone Laboratories, Logan, Utah), 1 . 2mM monothioglycerol (Sigma Chemical 
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Company, St. Louis, MO), 2mM L-glutamine, 50�g/ml gentamicin, 1 00U/ml penicillin, and 
l OO�g/ml streptomycin at 3 7 " C  and 5% CO2 . 
Total RNA was extracted from surgical tissue and cultured cells in this laboratory 
using the Ultraspec™-II RNA isolation system (Biotecx Laboratories, Inc, Houston, TX), 
which involves extraction with acid guanidinium thiocyanate and phenol-chloroform 
(Chomczynski and Sacchi, 1 987) .  
Primary human fibroblast cultures designated 8N, Edwards, 1 6BN, and 3 0K were 
established and maintained in the laboratory of Dr. Dome Yager (Division of Surgery, 
Department of Medicine, Virginia Commonwealth University, Richmond, Virginia), who 
kindly provided total RNA samples extracted from the cells . RNA specimens from the small 
cell lung cancer cell lines H 1 46, H209, H249, and WBA, and from the breast cancer line 
MCF7, were the generous gifts of Dr. Geoffrey Krystal (Division of Hematology IOn co logy, 
Department of Medicine and Department of Microbiology and Immunology, Virginia 
Commonwealth University and McGuire VA Medical Center, Richmond, V A) . 
Cytokines and growth factors 
Recombinant mouse interleukin-3 (rmIL-3) and recombinant mouse stem cell factor 
(nnSCF) were purchased from BioSource International, Camarillo, CA. Recombinant murine 
stem cell factor used in the in vivo experiments involving intraperitoneal injections (rmSCFI69) 
was cloned and expressed in this laboratory (see below) . 
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Cloning, expression, and purification of rmSCP69 
The production of recombinant mouse SCFl69 was accomplished by Dr. Julie Leftwich, 
a postdoctoral fellow in this laboratory, and has not been reported elsewhere. Therefore, the 
protocol used is briefly stated here. A clone of mouse SCF was obtained by screening an NIH 
3T3 cDNA library in a Lambda Zap II vector (Stratagene, La Jolla, CA) with a 5 '  end-labeled 
3 0  base o ligonucleotide probe (nucleotides 25 1 -28 1 )  derived from the published sequence 
(Zsebo et al . ,  I 990b ) .  Nitrocellulose filters lifted from the library were incubated for 1 8  hours 
at 37 °C  with 1 06 cpm/mJ of probe. The filters were washed 4X at 3 7 " C  for 10 minutes with 
2X SSC, 0 .2% sodium dodecyl sulfate (SDS), followed by one wash at 5 0 ° C  for 30 minutes 
with 0.5X SSC, 0.2% SDS. I of3 positive clones was chosen from 1 06 original plaques, and 
in vitro excision using the R408 helper virus was performed. The resulting pBluescript 
phagemids containing the cDNA were transfected into XL- I Blue host cells. The clone was 
sequenced using the Sequenase Version 2 kit (United States Biochemical, Cleveland, OH) and 
the coding gene region was found to have identical predicted peptide sequences as those 
published (Zsebo et aI . ,  1 990b) . 
To express recombinant SCF proteins, BglII-BSU36I fragments encoding the secreted 
form of SCF were subcloned into PET-3d utilizing a 5 '  l inker adding an Ncol site and a start 
codon and a 3' linker adding a stop codon and a BamHI site. These manipulations placed the 
coding region under the control of a T7 promoter which is inducible by the addition of 
isopropylthiogalactoside (IPTG) . The expressed mRNA encodes a protein 1 69 amino acids 
long, and has been designated rmSCFI69 . 
To purify rmSCFl69 protein, expression vector-containing bacteria were grown at 
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28 ° C  i n  LBlMglglucoseJamp to an OD600 of 0 .6-0 . 8  at which time IPTG was added t o  a final 
concentration of 0 . 8  mM. The cells were cultured an additional 2 hours, pelleted, and 
resuspended in lysing buffer. The cells were then subjected to French Press (PSI = 20,000) 
and the supernatant was clarified and partially purified using sizing chromatography. The 
resulting preparations of recombinant SCF proteins were approximately 80-90% pure. 
Surgical specimens 
Formalin-fixed, paraffin-embedded neurofibroma specimens were obtained from Dr. 
Audrey Steck (Division of Pathology, Department of Medicine, Virginia Commonwealth 
University, Richmond, VA). Additional neurofibroma tissue was generously provided by Dr. 
Fu-Tong Liu (Division of Allergy, La Jolla Institute for Allergy and Immunology, San Diego, 
CA) .  Prepared sections of formalin-fixed, paraffin-embedded malignant peripheral nerve 
sheath tumors were the kind gifts of Dr. David Viskochil (Division of Medical Genetics, 
University of Utah, Salt Lake City, UT). Fresh surgical specimens of vestibular schwannoma, 
acoustic neuroma, and meningioma tissues were kindly provided by Dr. William Broaddus 
(Division of Neurosurgery, Department of Medicine, Virginia Commonwealth University, 
Richmond, VA) . 
Bone marrow-derived murine mast cells 
Mouse bone marrow cells were obtained by flushing femurs with a 22 gauge needle 
into 10 ml of cDMEM supplemented with 50 nglml recombinant mouse stem cell factor 
(rmSCF, BioSource International, Camarillo, CA) and 50 U/ml recombinant mouse 
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interleukin-3 (rmIL-3 ,  BioSource) . The cells were initially maintained i n  a 25  cm2 tissue 
culture flask in a humidified chamber at 3 r C  and 5% CO2 , After overnight incubation, the 
non-adherent cells were transferred to a fresh 25 cm2 flask and placed back into the incubator, 
while the adherent cells were discarded. After the second night of incubation, the cell 
suspension was removed and centrifuged. The medium was discarded and the cell pellet was 
resuspended in a 75 cm2 tissue culture flask in 30 ml of cDMEM supplemented with rmSCF 
and rrnIL-3 at the above concentrations. The culture was maintained for a total of 4 weeks, 
with non-adherent cells being removed, centrifuged, and resuspended in fresh medium every 
3 -7 days. 
Conditioned media from Schwann cells of NFl-deficient mice 
Schwann cell-conditioned media from wild type and NFl-deficient mice were the 
generous gifts of Dr. Nancy Ratner (Department of Cell Biology, Neurobiology and Anatomy, 
College of Medicine, University of Cincinnati) . Schwann cell cultures were establi shed from 
excised peripheral nerve tissue of embryonic C57BLl6 mice bearing a targeted mutation of 
the NFl gene on either one (+/-) or both (-/-) alleles. Schwann cells derived from wild-type 
(+/+) mice were used for comparison. 
Murine mast cells grown in Schwann cell-conditioned media 
Mouse bone marrow-derived mast cells, after three weeks of culture in rmSCF and 
rmIL-3 (see above) were seeded onto a 96-well tissue culture plates at a density of 5 x 1 05 
cells/ml ( 1 05 cel ls/well) in cDMEM. The media in various wells contained either no 
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conditioned medium (control), 1 0% conditioned medium from cultures of BALB/c 3T3 
fibroblasts (FCM), 1 0% conditioned medium from cultures of Schwann cells derived from 
wild type C57BLl6 mice (NFl +1+ SCCM), 1 0% Schwann cell-conditioned medium from 
mice which were heterozygous for a disruption in the NFl gene (NF l +1- SCCM) (Jacks et 
aI . ,  1 994), or 1 0% Schwann cell-conditioned medium from homozygous NFl "knockout" 
mice (NFl -1- SCCM). Each of these categories included media supplemented with either 50  
nglml rmSCF, 50 Vlml rmIL-3 ,  both factors, or no  added factors. After 4 -7  days of culture 
under these conditions, representative plates were examined for mast cell granule phenotype, 
as determined by alcian blue/safranin staining (see below), and rate of proliferation, assessed 
by 3H-thymidine incorporation (see below). 
Alcian bluelsafranin staining of murine mast cells 
Partial phenotypic characterization of bone marrow-derived murine mast cells was 
accomplished using a two-step staining protocol (Enerback, 1 966). Cells were transferred 
to slides using a Cytospin 2 (Shandon, Inc. ,  Pittsburgh. PA) .  Preparations were first covered 
with 0 .5% alcian blue in 0 .3% glacial acetic acid for 5- 1 0  minutes, rinsed with tap water, and 
covered with 0 . 1 % safranin in 0 . 1 % glacial acetic acid for an additional 5 - 1 0  minutes .  The 
sl ides were again rinsed with tap water and air dried, and coverslips were mounted using 
Cytoseal™ 60 (Stephens Scientific, Riverdale, NJ) . Heparin, which can be found in the 
secretory granules of cells of the connective tissue mast cell (CTMC) phenotype, retains the 
safranin stain, resulting in the appearance of pink or red granules. Mucosal mast cells (MMC) 
do not contain heparin, and they stain alcian blue positive. 
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Proliferation assays for mast cells and Schwann cells 
Cultures of mast cells and Schwann cells grown in 96-well plates were "pulsed" by 
addition of 1 �Ci of 3H-thymidine (lCN Pharmaceuticals, Inc. ,  Costa Mesa, CA) to each well, 
followed by continued incubation for 4-24 hours. The samples were collected onto glass fiber 
filters using a Filtermate 1 96 Harvester (Packard, Meriden, CT), and the amount of 3H_ 
thymidine incorporation was determined using the TopCount scintillation counter (Packard) .  
The level of incorporation is proportional to the rate of proliferation of the cells in the sample .  
Immunofluorescence for the detection of Kit on malignanl schwannoma cell lines 
Each of four human malignant schwan noma cell lines, and the KEL-FlB human 
fibroblast line (negative control) were cultured at low density on 2-well chamber slides (Nunc 
Inc . ,  Naperville, IL) in cDMEM until firmly attached. The non-adherent HMC- I cell line 
(positive control) were grown in a tissue culture flask and then transferred to slides using a 
Cytospin 2 (Shandon, Inc . ,  Pittsburgh, PA). All specimens were fixed by immersion in 
acetone for 1 5  minutes at _20 ° C, drained, rinsed in deionized water and dried. 500�1 of 
blocking solution (1 % BSA, 100mM Tris pH 7.4,  1 5 0mM NaCI) containing I O�g/ml human 
IgG were added to each chamber, and slides were incubated at 4 ° C  for 30 minutes. The 
blocking solution was removed and replaced with blocking solution containing either 20�g/ml 
anti-human c-kit or IgG, isotype control antibodies, followed by incubation at 4 ° C  for 20 
hours. S lides were washed 3 times in wash solution ( l OOmM Tris pH 7.4, 1 50mM NaCI) for 
1 0  minutes each. 0 . 5ml of a I : 5 00 dilution of a biotinylated F(ab ' ), goat anti-mouse IgG in 
blocking solution was added to each slide for I hour at 4 ° C .  Sl ides were again washed three 
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times in washing solution, and then incubated one hour in O . Sml of blocking solution 
containing a I 1 000 dilution of streptavidin-FITC at 4 ° C  in the dark . Coversl ips were placed 
on the slides using 5% N-propyl gallate (S igma Chemical Company, St .  Louis, MO) to 
prevent quenching. S lides were analyzed on the Meridian Ultima confocal interactive laser 
cytometer (Meridian Instruments, Inc . ,  Okemos, MI). 
Immunohistochemistry to detect Kit ill neur()fibroma and malignant schwannoma lissue 
Immunohistochemical staining for human Kit was performed using standard 
techniques. Briefly, slides containing formalin-fixed, paraffin-embedded tissue sections were 
deparaffinized in xylenes and rehydrated in a series of graded ethanol washes. Endogenous 
peroxidase activity was blocked with 0 . 3% H202 in methanol . A polyclonal rabbit anti-Kit 
antibody was used as the primary antibody at a concentration of O .  5 11 g/m I. This antibody was 
then localized using the Vectastain Elite Kit (Vector Laboratories, Burlingame, CA) .  
Diaminobenzidine (Vector Laboratories) was used a s  the color substrate. 
Quantitative reverse transcription polymerase chain reaction of mouse SCF 
A quantitative RT-PCR protocol was developed which requires the use of a specially 
designed "cRNA control fragment" in competitive reactions with RNA isolated from the cel ls 
under study. This cRNA controls for variations during reverse transcription, and serves as 
an internal standard for the polymerase chain reaction.  A murine stem cell factor control 
fragment was constructed by inserting a 102 base pair piece of double-stranded ON A into our 
m S CF clone. The insert was obtained by digesting the plasmid pBluescript II SK+ 
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(Stratagene Cloning Systems, La Jolla, CA) with the restriction enzymes KpnI and SstI . The 
products were separated by agarose gel electrophoresis, and the band corresponding to the 
1 02 bp fragment was cut from the gel and minced with a razor blade. The DNA was 
extracted from the agarose by adding phenol, vortexing for 30  seconds, and incubating in a 
dry ice and ethanol bath for 5 minutes. After centrifugation, the fragment was precipitated 
from the aqueous phase by addition of 3M sodium acetate and 95% ethanol, followed by 
overnight incubation at minus 20 ° C .  
Our mouse SCF clone was digested with NsiI, which cuts a t  a single site within the 
SCF sequence (nucleotide 492 by the numbering of Anderson, et ai , 1 990), but does not cut 
the vector (pBluescript II SK+). This plasmid and the insert fragment were blunt-ended with 
T4 DNA polymerase. Both samples were then incubated with calf intestinal alkaline 
phosphatase (ClAP) to remove 5 '  phosphate groups, fol lowed by phenol-chloroform 
extraction and ethanol precipitation. A blunt end ligation was performed using T4 DNA 
ligase at a plasmid : insert ratio of I :  1 00 .  
E. coli XL I  blue bacteria were made competent for transformation by incubating in  
cold 1 00 mM CaCl2 for 10  minutes on ice. Cells were transformed by treatment with DMSO 
and addition of the products of the ligation reaction, followed by 3 0  minutes incubation on 
ice. Bacteria were heat-shocked by incubating in a 42 ° C  water bath for 90 seconds, and then 
chilled on ice. Bacteria were grown in Luria broth (LB) containing no antibiotics for an hour 
in a 3 7 " C  shaker. Samples were then streaked onto LB agar plates containing ampicillin and 
incubated at 3 7 " C  overnight. Colonies were plucked and subcultured in liquid LB containing 
ampicillin and incubated overnight at 3 r C  with shaking. 
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Plasmid DNA was extracted from the bacterial cultures using the Insta-Prep Kit (5 '  
to 3 ', Inc . ,  Boulder, CO). Samples were digested with the restriction enzyme XhoI to 
determine if an insert had been ligated into the plasmid.  The vector, pBluescript II SK +, 
contains a single XhoI site. The 1 02 base pair insert also contains this site. If the insert is  
missing, the enzyme cuts at only one site. If it is present, two sites are cut, releasing a 
fragment of 594 base pairs. A clone containing the insert was chosen, and submitted to the 
MCV Molecular Biology Core Facility for large-scale plasmid preparation. The cRNA was 
generated by in vitro transcription using T7 RNA polymerase. The control fragment contains 
the same primer binding sites as natural SCF mRNA, but will generate an RT-PCR product 
which is 1 02 base pairs larger. 
For competitive RT -PCR, decreasing amounts of control fragment RNA of known 
concentrations are added to a series of tubes containing a constant amount of total cellular 
RNA. Standard reverse transcription and polymerase chain reactions are carried out, resulting 
in competition between the two templates for primers and other reaction components. 
Following amplification, the products are resolved by agarose gel electrophoresis and 
subjected to Southern blot analysis (see below) . The intensities of the bands on the resulting 
auto radiograph are compared by densitometry. The quantity of mRNA in the original 
unknown sample is ascertained by determining the amount of control fragment needed to 
generate a band of equal intensity. 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
The standard RT-PCR protocols used in this study were performed using the 
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GibcoBRL Superscript Preamplification System (Life Technologies, Inc . ,  Baltimore, MO), 
supplemented with AmpliTaq® DNA Polymerase (Perkin Elmer, NOIwalk, CT). 
The reverse transcription reaction was carried out by adding I llg total RNA in a 
volume of J ill to a reaction tube containing 1 0 11 1  Milli-Q water. After addition of I Il I  of a 
21lM gene-specific antisense oligonucleotide primer, the mixture is incubated at 70 ° C  for 1 0  
minutes and then quickly chilled o n  ice for at least I minute. 711 1  of a master mix containing 
2111 l OX peR buffer, 2111 25mM MgCI2' I Il I  1 0mM dNTP mix and 2111 0 1M DTT are added 
to each tube, followed by a 5 minute incubation at 42 °C .  After addition of I Il I  (200U) of 
SuperScriptTM II RNase H- reverse transcriptase, the 42 ° C  incubation is continued for an 
additional 50 minutes. The reaction is terminated by incubating at 70 ° C for 1 5  minutes. 
After another quick chill on ice, the contents are collected by brief centrifugation, followed 
by the addition of J il l  (2U) E. coli RNase H and a 20 minute incubation at 3rc .  
The polymerase chain reaction was performed by  first adding 211 1  of  each RT reaction 
to a fresh tube. 23 111 of a master mix containing 1 8 11 1  water, 2 . 5 11 1  l OX PCR buffer, l . 5 1l1 
MgCI" and l . 01l1  1 0mM dNTP mix are added to each reaction. One paraffin bead 
(Ampliwax® PCR Gem 1 00 [Perkin Elmer] or equivalent) is added to each tube, followed by 
a 5 minute incubation at 80 ° C  to melt the wax. After allowing the paraffin to reharden at 
room temperature, 2511 1  of a master mix containing 1 8 . 5 11 1  water, 2 . 5 11 1  l OX PCR buffer, 
l . 5 1l 1 2 5 mM MgCI" l . 01l 1  J OIlM sense primer, l . 01l1 1 0ilM antisense primer, and 0 . 5 11 1  
(2 . 5U) AmpliTaq® DNA Polymerase were added onto the top  of  the wax barrier. 
The PCR reactions were carried out in the GeneAmp® PCR System 9600 (Perkin 
Elmer) using programs optimized for the primers and templates being used . For mouse stem 
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cell factor, 30  cycles were performed as follows: denature at 94 ° C for 1 5  seconds, anneal at 
5 5 ° C  for 15 seconds, and extend for 3 0  seconds at n ° e .  Reaction products were resolved 
by agarose gel electrophoresis .  For most applications, a standard 1 %  agarose gel was used, 
but for quantitative RT -PCR reactions, 4% NuSieve® 3 :  I agarose (FMC BioProducts, 
Rockland, ME) was used to better resolve fragments with small size differences. Bands were 
visualized by staining with ethidium bromide and viewing on a UV light box. 
Southern blotting 
After agarose gel electrophoresis, gels were soaked for 40 minutes in a denaturing 
solution containing 1 . 5M NaCI and 0 . 5M NaOH. Gels were then soaked two times (30 
minutes each) in a neutralizing solution containing 1 . 5M NaCI and 1M Tris pH 8 . 0 .  Nucleic 
acid transfer was accomplished by downward capillary action as follows: a piece of thick filter 
paper, cut to gel size, was soaked 20 minutes in l OX SCC and placed on a 5 inch stack of 
paper towels in a basin. This was followed by 2 pieces of thin filter paper (also cut and 
soaked), a piece ofO.2�m Nytran® (Schleicher and Schuell, Keene, NH), the gel (soaked 1 0  
minutes in l OX SSC), a third piece of thin filter paper, and a sponge soaked in l OX SSe .  The 
entire container was wrapped in plastic wrap and left undisturbed overnight . After transfer, 
the orientation of the wells were marked on the nytran with a needle, and the DNA was cross­
l inked to the Nytran using a UV Stratalinker™ 1 800 (Stratagene, La Jolla, CA). 
Oligonucleotide probes were labeled using the GibcoBRL 5 '  end labeling kit (Life 
Technologies, Inc. ,  Baltimore, MO). 1 00ng of probe in 1 7�1 water were mixed with 2� 1  T4 
kinase ( I OU), 6�1  l OX forward reaction buffer, and 5� 1  [y _32p]ATP ( i 50�Ci/�I) .  After 
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incubating at 37"C for one hour, the reaction was terminated by incubating for 10 minutes at 
65 ° C .  The labeled probes were then hybridized to the blots using a Hybaid hybridization 
oven (Hybaid Instruments, Holbrook, NY) . The Nytran filters and nylon mesh were briefly 
soaked in sterile water, layered upon each other, rolled into a tube and placed in a 
hybridization bottle .  A 2X prehybridization solution was prepared by mixing l 25mg yeast 
RNA (mixed in I ml water and a few drops ofNaOH), 2 . 5ml 20% SDS, 0 . 5g  bovine serum 
albumin, 0 . 5g  polyvinylpyrrolidone (PVP), 0 .5g ficoll, 25ml 1M sodium phosphate pH 6 . 5 ,  
and 1 25ml 20X SSC, brought t o  a total volume o f  250m I with water. 1 0mi o f  a 1 . 1  mixture 
of2X prehybridization solution and water were added to the bottle containing the blots, and 
the bottle was incubated in the hybridization oven for 1 hour at 3 7 "  C .  This solution was then 
poured off and replaced with fresh 1 . 1  prehyb mix and water to which the entire probe 
labeling reaction was added. The blots were incubated with the probe overnight in the oven 
at 37 "C .  After disposing of the solution into the appropriate radioactive waste container, the 
blots were washed twice ( 1 0  minutes each) in 30ml of2X SSC/O . I %  SDS at 3 7 " C, followed 
by a 1 hour wash in 50ml of O .2X SSC/O . I %  SDS at 3 7 ° C .  The excess liquid was blotted 
from the filters with paper towels, the blots were covered in plastic, and placed on x-ray fi lm 
for 24 hours (exposure time varies with the strength of the signal) .  
Ribonuclease protection assay (RP A) for SCF iso/arms 
Total RNA was obtained by using the UItraspec™ RNA i solation system (Biotecx 
Laboratories, Inc . ,  Houston, TX) . Samples were stored at -80 ° C  at concentrations of 1 -2 
�g/� I  until needed . The probe was generated by PCR amplification of a fi'agment of our 
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cloned human stem cell factor cDNA (Ryan e t  aI , 1 994) including most of exons 5 and  6 
(nucleotides 560-78 1 as numbered by Martin et aI , 1 990) . The following primers were used 
Primer I :  5'-ATGGGATCCATTCAAGAGCCCAGAAC-3 '; primer 2 5 '-GCTCTAGA TGC 
TACTGCTGTCATTCC-3 ' .  Nucleotides in bold type represent restriction sites for BamHI 
and Xbal, respectively. After amplification, the fragment was digested with the two enzymes 
and ligated into pBluescript II SK+ (Stratagene Cloning Systems, La Jolla, CA), which had 
been similarly digested . A radiolabeled transcript was obtained with the MAXIscriptTM In 
Vitro Transcription Kit (Ambion, Inc . ,  Austin, TX) using T3 RNA polymerase and [a_·np] 
UTP. RNase Protection Assays (RPA) were performed with the RPA JITM kit (Ambion), 
fol lowing the suggested protocol Fragments were resolved on a 5% acrylamide 8M urea 
sequencing gel Protected fragments of 222 and 1 44 nucleotides are indicative of the exon 
6-containing (soluble) and exon 6-lacking (membrane-bound) isoforms of human SCF mRNA, 
respectively. 
ELISA for human SCF 
Conditioned media were assayed for immunoreactive stem cell factor using a 
Quantikine™ human SCF kit (R&D Systems, Minneapolis, MN). The kit contains all the 
necessary antibodies and standards, and the manufacturer' s  suggested protocol was followed. 
The plates were read at 450 nm on a V -max Kinetic Microplate Reader (Molecular Devices 
Corp . ,  Palo Alto, CA) .  The range of the assay was from 3 1 . 25 to 1 000 pglml 
Results 
In vivo effects of intraperitoneal injections of rmSCF'69 
To determine if intraperitoneal SCF injections might lead to the migration of mast cell 
precursors into the peritoneal cavity and subsequent maturation and proliferation, mast cells 
in the peritoneum were quantitated. Mice were given daily intraperitoneal injections of 3 �g 
ofrmSCF169 in 1 00 �I sterile phosphate-buffered saline (PBS) .  A control group was injected 
daily with PBS alone. After 16 days of injections, a group of SCF-treated mice and a group 
of control mice were infected with the hookworm Nippostrongylus brasiliensis (Nb) by 
subcutaneous injection of 600 stage 3 larvae/mouse in 200 �I PBS .  Mice were sacrificed after 
22 days of SCF (or PBS) injections. In Nb-infected animals, this corresponded to day 7 post 
infection.  Five ml of a 0 .22 M sucrose solution were injected into the peritoneal cavity, 
followed by gentle massage to dislodge cells. After the muscle membrane lining the cavity 
was surgically exposed, the fluid was removed with a Pasteur pipette through a small hole in 
the membrane. The cel ls in these samples were transferred to slides with a Cytospin 2 
cytocentrifuge, and stained with acid toluidine blue to detect mast cells . Although peritoneal 
wash-out cells such as these are a rich source of mature mast cells in untreated mice, the 
numbers were markedly decreased in response to SCF treatment (Figure I ). As previously 
reported, peritoneal mast cell numbers were also greatly diminished in response to Nb 
infection alone (Huff et aI . ,  1 995) .  
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Figure 1 .  Effects of rmSCFl69 injections o n  peritoneal mast cell numbers. Mice were given 
daily intraperitoneal injections of PBS alone or 3 ).Ig of rmSCFl69 in PBS for 22 days, at which 
time the mice were sacrificed. Nb infection was established by subcutaneous injection of 600 
stage 3 larvae of the hookworm Nippostrongy/us brasiliensis seven days prior to sacrifice. 
Cytospin preparations of peritoneal washouts were stained with 0 .2% acid toluidine blue, and 
mast cells were enumerated . Data represent the mean ± SEM of mast cell counts in five 
random 20X microscopic fields from three mice. 
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Next we  wished to determine i f  mast cell numbers might be systemically affected .  
Subcutaneous injections of SCF have been shown to result in a local mast cell hyperplasia at 
the site of injection (Zsebo et a! . ,  1 990b; Tsai et a! . ,  1 99 1 ) .  We tested to determine if 
prolonged intraperitoneal injections of high doses of rmSCF169 would lead to a systemic 
increase i n  mast cell numbers. Mice were sacrificed and five ml of air were injected 
subcutaneously into the back skin of mice just over the spine. The back skin was then everted 
to reveal a transparent bubble of dermal tissue. This tissue was dissected away and dermal 
spreads were prepared on slides. After air drying, the slides were stained with 0 . 2% acid 
toluidine blue and the mast cells were counted. No significant difference in the number of 
mast cells was observed between control and SCF-treated subjects after 22 days of injections 
(and 7 days ofNb infection, where applicable), suggesting that intraperitoneal administration 
of high doses of SCF does not appear to cause a systemic mast cell hyperplasia (Figure 2). 
Having demonstrated that mast cell numbers were locally but not systemically 
decreased, we wished to determine if intraperitoneal SCF treatment might affect Nb egg 
production and worm expulsion. The degree ofNb infection in control and SCF-treated mice 
was monitored by performing daily fecal egg counts on days 4- 1 1  following larval injections. 
To do this, we collected feces by housing the mice in wire bottomed cages .  Fecal droppings 
were collected on moist paper towels, retrieved, and eggs were counted using the OvassayTM 
fecal diagnostic system (pitman-Moore, Inc . ,  Mundelein, IL) . The results of this experiment 
are shown in  Figure 3 .  No significant differences were noted in the number of Nb eggs 
expelled by either PBS control or SCF-injected animals. As an alternative means to determine 
the severity of infection, adult Nb worms in the small intestines of mice sacrificed on days 7 
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Figure 2 .  Effects of rmSCF169 injections on  dermal mast cell numbers . rmSCF169 injections 
and Nb infections were performed as in Figure I legend . Dermal tissue was obtained by 
injecting a 5 ml air bolus under the skin just over the spine. Skin was surgically everted, and 
the membranous dermal tissue was excised and placed on sl ides .  After air drying, the slides 
were stained with acid toluidine blue. Data represent the mean ± SEM of mast cell counts in 
5 random 20X microscopic fields from 3 mice. 
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Figure 3 .  Effects ofnnSCF169 injections o n  severity of Nippostrongylus brasiliensis infection : 
fecal egg counts. Nb-infected mice were housed in wire-bottomed cages, and fecal droppings 
were col lected every 24 hours for the indicated days. Nb eggs were counted using a 
commercial fecal diagnostic kit. Data represent the mean ± SEM of counts obtained from 
triplicate test subjects .  Injections and Nb infections were performed as described in Figure 
1 legend. 
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and 1 6  post infection were counted. The small intestine ( 1 5  c m  section) o f  each mouse was 
removed and opened using surgical scissors. The worms were counted using a dissecting 
stereomicroscope either directly in the gut section, or as a suspension in PBS .  As seen in 
Figure 4, a large number of worms were observed in the gut of both control and SCF-treated 
mice after 7 days ofNb infection, and the worms were completely cleared in both groups by 
day 1 6. This time course is consistent with previous results in our laboratory using this model 
system. Stem cell factor injections did not appear to have any effect on the number of worms 
in the small intestine, or on the rate at which they were cleared. 
Quantilation of stem cell factor isoforms by competitive RT-PCR 
As a result of differential splicing and postranslational events, human stem cell factor 
can be found as a soluble or membrane-bound protein (Anderson et aI . ,  1 990; Anderson et 
aI . ,  1 99 1 ;  Flanagan et aI . ,  1 99 1 ) .  The biological activities of SCF/Kit interactions include 
adhesion, migration (by way of chemotaxis or haptotaxis), survival, proliferation and 
differentiation, and in some cases, activation (reviewed in Galli et aI . ,  1 994), and significantly 
different activities have been associated with each isoform (Toksoz et aI . ,  1 992). We 
therefore felt that it was reasonable to hypothesize that altered regulation of SCF isoform 
expression may have pathological consequences. 
To evaluate the levels of expression of one isoform compared to the other, we set out 
to develop a means to quantitate the relative amounts of each mRNA produced by a given 
population of cells. This laboratory had previously designed a competitive reverse 
transcription polymerase chain reaction (RT-PCR) protocol with which to quantitate levels 
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Figure 4 .  Effects ofrmSCF'69 injections on severity of Nippos/rangy/lls brasiliensis infection: 
adult worm counts. Daily injections and Nb infections were performed as in Figure I legend. 
Mice sacrificed at day 16 post infection received continued daily injections of rmSCF'69 or 
PBS (3 1 days total) .  15 cm sections of small intestines were removed, and adult Nb worms 
were counted. Data represent the mean ± SEM of worm counts in four mice. No worms 
were seen in any of the mice at day 1 6 . 
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ofmRNA expression for the gamma chain of the murine high-affinity IgE receptor (Fc.RIy) .  
We used an adaptation of this technique in an attempt to determine the quantities of mRNAs 
for both isoforms of stem cell factor. 
As described in Materials and Methods, this protocol involves the use of a panel of 
known quantities ofa cRNA control fragment which is co-transcribed and co-amplified in the 
RT-PCR reactions with cellular RNA, resulting in a competitive advantage for the species of 
higher molar concentration. The products are distinguished from each other by agarose gel 
electrophoresis, based on their size differences, and the relative quantities are determined by 
comparing the densities of the resulting bands. The original amount of target mRNA can be 
calculated based on the amount of cRNA control fragment needed to generate a similar 
amount of product. We initially developed a protocol to evaluate mouse SCF expression. 
By  using an antisense PCR primer which targets a sequence within exon 6, the quantity of 
mRNA for the soluble isoform can be determined. In a separate set of reactions using an 
antisense primer which anneals upstream of exon 6, the combined quantities of both isoforms 
is obtained. The molar concentration of the membrane-bound isoform is calculated by 
subtracting the value obtained for the soluble isoform of mRNA from that obtained for the 
combined forms. 
The results ofa representative experiment are shown in Figure 5. The DNA from this 
gel was subjected to Southern blot analysis and visualized by hybridization with a radiolabeled 
oligonucleotide probe, followed by autoradiography (see Materials and Methods). In this 
experiment, the amount of SCF mRNA in I Ilg of total cellular RNA (the amount added to 
the original reaction mixture), is  determined to be between 0.2 and 2 . 0  picograms, based on 
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Figure 5 .  Competitive RT-PCR for quantitation of mouse SCF mRNA. A constant amount 
(I Ilg) of total RNA from BALB/c 3T3 fibroblasts was added to decreasing amounts of mSCF 
cRNA control fragment, as indicated . Samples were then reverse transcribed to cDNA and 
amplified by polymerase chain reaction. Shown is an autoradiograph of the Southern blot of 
the amplified products. 
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the relative intensities of the bands .  Alternatively, the  bands on an auto radiograph can be 
assigned numerical values by densitometry, allowing for more accurate calculations. 
We developed a similar protocol for the evaluation of human SCF. However, 
although the technique is highly sensitive and can be performed on very small quantities of 
RN A, we concluded that it is overly labor intensive in requiring a dose response curve for 
each experimental sample. Therefore we sought to detennine if our samples could be assayed 
using a ribonuclease protection assay (RP A), which is ten times more sensitive that Northern 
analysis, and could be used in side-by-side comparisons between samples. 
Two isoforms of human stem cell factor messenger RNA can be detected by a ribonuclease 
protection assay 
Schwann cells are a source of SCF (Ryan et aI . ,  1 994) and mast cells, which express 
Kit and respond to SCF, are hyperplastic in neurofibromas (Isaacson, 1 976). In light of the 
above mentioned activities associated with the two isoforms of SCF (and their possible 
contributions to pathological conditions), we set out to examine the expression of stem cell 
factor isoforms in tissues from NF l and non-NF l patients. 
In an effort to acquire a means by which the two isoforms of human stem cell factor 
messenger RNA (SCF mRNA) could be discretely detected, a ribonuclease (RNase) 
protection assay (RP A) was developed. RP A involves hybridization of a radiolabeled RNA 
probe to a target mRNA by complementary base-pairing, and subsequent ribonuclease 
digestion of all unhybridized RNA. This study utilizes a probe which is complementary to the 
sequence encoding most of exons 5 and 6 of the SCF mRN A. A protected fragment 222 
64 
nucleotides in length results from hybridization of the probe with an mRNA which includes 
sequence encoded by exon 6 (the soluble isoform). When exon 6 is absent, as in the case of 
the membrane-bound isoform, the protected fragment is  1 44 nucleotides long (see Figure 6) .  
To assess the ability of the RPA to detect the mRNA isoforms, the procedure was 
performed on total RNA extracted from human fibroblast-derived cell lines, because 
fibroblasts are known to express SCF (Kitamura et aI. ,  1 989; Fujita et aI . ,  1 989; Kitamura and 
Fujita, 1 989; Jarboe and Huff, 1 989). Autoradiographic analysis of the gel reveals that bands 
representing protected fragments of apparent lengths of 222 and 1 44 nucleotides result, 
indicating that SCF mRNAs have been detected for the soluble and membrane-bound 
isoforms, respectively (Figure 7). 
In addition to the fibroblast-derived cell l ines, we performed the procedure on RNA 
extracted from primary human fibroblast cultures which had been derived by explantation of 
surgical skin tissue. In 7 out of 7 samples tested, a band corresponding to a protected 
fragment of 222 nucleotides was observed, suggesting expression of the soluble isoform of 
SCF mRNA (Figure 8) .  As part of a collaborative effort led by Dr. Dome Yager (Division 
of Surgery, Department of Medicine. Virginia Commonwealth University, Richmond, 
Virginia), we included primary fibroblasts derived from keloid tissue in this study. Keloids 
are characterized as progressively enlarging scars resulting from excessive collagen deposition 
during connective tissue repair, and Dr. Yager' s  work includes investigation of the 
mechanisms by which keloids are formed. We sought to evaluate whether a change in SCF 
i soform expression by the resident fibroblasts played a part in this mechanism. Our 
preliminary conclusions are that there appears to be no change in SCF isoform expression by 
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Figure 6. Ribonuclease protection assay for human SCF mRNA. Schematic representation 
of the hybridization specificity of the probe used for RPA. 
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Figure 7 .  Autoradiograph of RPA on human fibroblast-derived cell lines. RPA was 
performed on 10 Ilg of total RNA as described in Materials and Methods. The human 
fibroblast cell lines used are : (lane I) CCD I 8 ; (lane 2) Detroit 5 5 1; (lane 3) HS68; (lane 4) 
KEL-FIB; (lane 5) MRC-9. Size markers (M) are shown to the left. Expected fragment sizes 
of 222 and 144 nucleotides indicating the soluble and membrane-bound isoforms of SCF 
mRNA, respectively, are indicated. 
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69 
Figure 8 .  Autoradiograph of RP A on primary human skin fibroblasts. RP A was performed 
on 1 0  Ilg of total RNA extracted from cultures of primary fibroblasts established by 
explantation of human skin tissue. Data are representative of seven subjects tested. Samples 
are: (lane I) 8N-normal skin; (lane 2) Edwards-keloid tissue; (lane 3 )  1 6BN-normal skin from 
an Afiican-Amencan donor; (lane 4) 3 0K-keloid tissue. S ize markers (M) are represented at 
the left. Arrow indicates expected 222 nucleotide fragment size for the soluble isoform of 
SCF rnRNA. 
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keloid-derived fibroblasts, compared to those derived from normal skin. 
Human malignant schwannoma cell lines express only the membrane-bound isoform of stem 
cell factor messenger RNA 
The malignant schwannoma is a rare form of cancer which seems to have an increased 
rate of incidence in NFl patients (Bernards et aI . ,  1 992). We obtained cell lines derived from 
four human malignant schwannomas and extracted RNA for analysis by RPA. In each of the 
four human malignant schwannoma cell lines, a protected fragment of an apparent length of 
1 44 nucleotides is seen (Figure 9, arrow), whereas no 222 nucleotide fragment is evident. 
These data indicate that the cell lines exclusively express mRNA for the membrane-bound 
isoform of SCF. 
Other human malignant cell lines do not exhibit exclusive expression of the membrane­
bound isoform of stem cell factor messenger RNA 
The preferential expression of membrane-bound SCF mRNA by the malignant 
schwannoma cell lines caused us to ponder whether this pattern of expression was in any way 
related to the transformed phenotype of the cell s . In order to determine if other human 
malignancies also expressed the membrane-bound form, we obtained total RNA samples 
extracted from human small cell lung carcinoma cell lines and a human breast cancer cell line, 
and examined them for similar patterns of expression. Each of the samples tested appears to 
express the soluble isoform of SCF mRNA (Figure 1 0) .  
72 
Figure 9. Autoradiograph of RPA on human malignant schwannoma cell lines. RPA was 
performed on 10 �g of total RNA extracted from malignant schwannoma cell lines as 
described in Materials and Methods. Samples are: (lane I) NF- I T; (lane 2) ST88- 1 4; (lane 
3)  STS-26T; (lane 4) T265.  Size markers (M) are shown. Arrow indicates the expected 1 44 
nucleotide fragment size for the membrane-bound isoform of SCF mRNA. 
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Figure 1 0 .  Autoradiograph of RP A on human small cell lung carcinoma cell lines and a 
human breast cancer-derived cell line. RPA was performed on 1 0  iJg of total RNA extracted 
from human small cell lung carcinoma (SCLC) cell lines or a breast cancer line as described 
in Materials and Methods. Samples are: (lane I) H I 46-SCLC; (lane 2) H209-SCLC; (lane 
3) H249-SCLC; (lane 4) WBA-SCLC; (lane 5)  MCF7-breast cancer line. S ize markers (M) 
are shown. Arrow indicates the expected 222 nucleotide fragment size for the soluble isoform 
of SCF mRNA. 
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Expression of the exon 6-containing mRNA correlates with release of soluble SCF protein 
Production of soluble stem cell factor involves at least two steps :  a splicing event 
which includes the exon 6-encoded sequence in the mRNA, and proteolytic cleavage of the 
protein, which is  initially expressed as a membrane-inserted protein (Anderson et aI . ,  1 99 1 ) . 
It is possible that SCF expression may be regulated, at least in part, at the proteolysis step (for 
example, no cleavage of an exon 6-containing protein, resulting in membrane-bound SCF). 
In  an effort to ascertain whether detection of exon 6-containing mRNA transcripts by 
ribonuclease protection assay correlated with release of soluble stem cell factor by the same 
population of cells, we performed a sensitive enzyme-linked immunosorbent assay (ELISA) 
on the culture supernatants of the cell lines used. SCF was detected in the supernatants of cell 
l ines which were found by RP A to express the soluble isoform of SCF mRNA (Figure 1 1 ) .  
However, the culture supernatants o f  the four malignant schwannoma cell lines, which 
expressed only mRNA for the membrane-bound isoform as determined by RPA, contained 
no detectable SCF (Figure I I ) .  
Neur()fibroma tissue and other Schwann cell-containing tumors express soluble SCF mRNA 
Total RNA was extracted from surgically excised neurofibroma, and subjected to RP A 
analysis .  Figure 1 2  indicates that this tumor expresses the soluble (arrow), but not the 
membrane-bound form of SCF mRNA. Other Schwann cell-containing tumors, including an 
additional neurofibroma, a vestibular schwannoma, and an acoustic neuroma were evaluated 
in  a similar fashion. For comparison, a meningioma specimen was also included in this 
experiment. No 1 44 nucleotide protected fragments were observed in any of the samples, 
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Figure 1 1 .  Enzyme-linked immunosorbent assay to detect soluble human SCF in cel l  culture­
conditioned media. ELISAs were performed on conditioned media from the indicated cell 
lines using a commercial kit. Results were obtained using an automated plate reader. 
CCD I 8, HS68, and MRC-9 are human fibroblast cell lines. HT I 080 is a human fibrosarcoma 
cell line which was shown by RP A to express the soluble isoform of SCF mRNA (data not 
shown). NF- I T, ST88- I4, STS-26T, and T265 are human malignant schwannoma cell lines. 
Sensitivity of the assay ranged from 3 1 .25  to 2000 pg/ml of human SCF. Data represent the 
mean of duplicate wells . Similar results were obtained in three separate experiments. 
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Figure 12 .  Autoradiograph ofRPA performed on neurofibroma tissue. 20 �g of total RNA 
extracted from neurofibroma tissue was subjected to RP A as described in Materials and 
Methods .  Size markers (M) are shown. Arrow indicates the 222 nucleotide expected 
fragment size for the soluble isoform of SCF mRNA. NF: neurofibroma. 
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while the majority of the tumors revealed a fragment of222 nucleotides, indicating expression 
of the soluble isoform of SCF mRNA (Figure 1 3 )  No SCF mRNA was detected in the 
meningioma tissue. 
Human malignant schwannoma cell lines exhibit low level expression of Kit 
Normal rat and human Schwann cells have been shown to express stem cell factor, but 
not its receptor, Kit (Ryan et aI . ,  1 994). In that study, however, it was found that the ST88-
14  human malignant schwannoma cell line simultaneously expressed both proteins, suggesting 
that these cells may proliferate in response to autocrine stimulation (Ryan et aI . ,  1 994). 
Having obtained three additional human malignant schwannoma cell l ines, we sought to 
determine if  they also expressed Kit. In the course of pursuing a related project in this 
laboratory, Christopher Shelburne analyzed the four cell lines by indirect immunofluorescence 
and confocal laser cytometry. Figure 14 indicates that each of the four lines exhibits 
fluorescence indicative of a low level expression of Kit (panels A-D). Corresponding samples 
incubated with a non-specific mouse IgG, showed no fluorescence (not shown) . Further 
analyses suggest that the Kit protein in each of these lines is truncated in some way, and bears 
a novel point mutation which may cause the receptors to be constitutively activated 
(manuscript in progress). HMC- I cells, which express Kit abundantly, are shown as a positive 
control (panel E). 
Kit is not detected on Schwann cells of neurofibroma or malignant schwannoma tumors 
Neurofibromas are composed primarily of Schwann cells, but include a few other cell 
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Figure 1 3 .  Autoradiograph of RP A performed on human Schwann cell-containing tumors. 
RPA was performed on 10 �g of total RNA extracted from human tumors as described in 
Materials and Methods. Tumors include: (lane 1) neurofibroma; (lane 2) acoustic neuroma; 
(lane 3 )  meningioma; (lane 4) vestibular schwannoma. S ize markers (M) are shown. Arrow 
indicates the expected 222 nucleotide fragment for the soluble isoform of SCF mRNA. 
83 
M 1 2 3 4 
300 
200 
1 00 
84 
Figure 14 .  Photomicrographs of indirect immunofluorescence to detect Kit protein expression 
by human malignant schwannoma cell lines. Cells were incubated with a monoclonal antibody 
against human Kit. Bound antibodies were visualized using a fluorochrome-labeled secondary 
antibody, followed by confocal laser cytometry. Samples are : (A) NF- l T; (B) ST88- 14 ;  (C) 
STS-26T; (D) T265 .  The human mast cell line HMC- l (E) were used as a positive control .  
The negative control was the KEL-FIB human fibroblast cell l ine (F) . 
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types, including mast cells. We wished to detennine whether these Schwann cells express the 
Kit receptor, offering a possible explanation for their hyperplasia. Sections of formalin-fixed 
paraffin-embedded neurofibromas were evaluated for the expression of Kit protein by 
immunohistochemistry as described in Materials and Methods. Mast cells are known to 
express Kit protein, and therefore serve as convenient internal controls for the staining 
protocol. Indeed, Kit protein was easily detectable on mast cells (Figure 1 5, arrows). The 
surrounding Schwann cells, however, show no evidence of immunoreactive protein. By using 
differential interference contrast microscopy at a higher magnification (Figure 1 6) we were 
better able to identifY the Schwann cells, based on their characteristic fibrillar morphology. 
The detection of Kit protein on all four of the malignant schwannoma cell lines led to 
our hypothesis that there may be a correlation between aberrant Kit expression by Schwann 
cells and a transformed phenotype.  However, the results of immunohistochemical analyses 
of malignant schwannoma sections did not support this hypothesis. Once again, Kit expression 
by mast cells was evident, but no Kit was detected on the Schwann cells of these tumors 
(Figure 1 7) .  
Growth of the HMC-I cell line is not supported by coclI/ture with or conditioned media from 
human malignant schwannoma cell lines 
In light of the fact that both Schwann cells and mast cells are found in increased 
numbers in neurofibromas (Isaacson, 1 976; Peltonen et aI . ,  1 988 ;  Johnson et aI . ,  1 989), and 
that Schwann cells make stem cell factor (Ryan et aI . ,  1 994), we wanted to investigate the 
possibility that either cell type may be inducing the proliferation of the other. We obtained 
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Figure 1 5 .  Photomicrographs of  immunohistochemistry to  detect Kit protein in neurofibroma 
tissue sections. (A) Immunohistochemistry was performed on neurofibroma sections using 
a polyclonal antibody agains human Kit as described in Materials and Methods. Arrows 
indicate Kit+ mast cells. (B) Adjacent section stained with an isotype-matched control 
antibody. Original magnification: 66X. 
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Figure 16 .  High magnification photomicrographs of immunohistochemistry to detect Kit 
protein in neurofibroma sections. Sections of neurofibroma depicted in Figure 1 5  viewed at 
a higher magnification. (A) Kit+ mast cell. (B) Adjacent section stained with an isotype­
matched control antibody. Original magnification: 3 3 0X. 
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Figure 1 7 .  Photomicrographs of immunohistochemistry to detect Kit protein i n  malignant 
schwannoma tissue sections. Immunohistochemistry was performed on thin sections of 
human malignant schwannoma tumors as described in Materials and Methods. (A) Section 
stained with a polyclonal antibody against human Kit. Arrows indicate Kit+ mast cells .  (B) 
Adjacent section stained with an isotype-matched control antibody. Original magnification :  
1 3 ZX. 
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the HMC-I cell line, which was derived from a patient with mast cell leukemia, and is thought 
to represent a human mast cell line (Butterfield et aI . ,  1 988), to grow in coculture with the 
malignant human schwannoma cell lines. 
Twelve separate experiments involving HMC- I cells in coculture with malignant 
schwannoma cell lines, or HMC- I cells grown in the presence of conditioned media (CM) 
derived from the schwannoma lines were performed. The proliferation of HMC- I cells, 
determined either by 3H-thymidine uptake assays or by increases in cell number, was not up-
regulated in any of the experiments. Typical results are represented in Figure 1 8 . Oddly, in 
early cultures ofHMC- 1 cells in the conditioned medium of the ST88- 1 4  schwannoma line, 
we noted a rapid demise of the HMC- I cells (data not shown) . The cell death was not 
occurring through an apoptotic pathway, according to the results of a terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Upon receipt of a 
different clone of the ST88- 1 4  line from Dr. Jonathan Fletcher (Department of Pathology, 
B righam and Women's  Hospital, Boston, MA), the experiments were repeated, and this 
phenomenon was no longer observed (Figure 1 9), suggesting that the original clone likely 
contained a toxic contaminant. 
Characterization of murine bone marrow-derived mast cel/s clllillred with Schwann cel/­
conditioned media from wild type or NFl-deficient mice 
Efforts to conduct experiments examining potential paracrine effects of mast cells and 
Schwann cells upon each other have been hampered by the difficulties involved in obtaining 
and maintaining relatively pure populations of normal human mast cells and Schwann cells .  
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Figure 1 8 .  Proliferation of HMC- I cel ls cocultured with irradiated human fibroblast or 
malignant schwannoma cell lines. Malignant schwannoma and KEL-FIB cells were irradiated 
with 127Cs (4000 rads) and seeded onto a 96 well plate. HMC- l cells were co cultured with 
the irradiated cells for 2 days. Each well was incubated for 4 hours after the addition of I IlCi 
of3H-thymidine, and the cells were harvested with a PHD cell harvester. Incorporation of 'H­
thymidine was determined using a scintillation counter. Data represent the mean ± SEM of 
triplicate wells .  
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Figure 19 .  Daily cell counts ofHMC-l cells grown in 25% ST88- l 4  CM. HMC- l cells were 
grown in a 25 cm2 flask in a 25% concentration of conditioned medium from cultured ST88-
14  human malignant schwannoma cells .  The number of viable HMC- l cells was determined 
daily by trypan blue exclusion. 
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The experiments described above were done with cel l  lines, which represent phenotypically 
abnormal cells, and therefore do not serve as an adequate model system. Primary cultures of 
mouse mast cells are routinely established in this laboratory, and attempts to isolate and grow 
highly purified cultures of mouse Schwann cells have been successful in other labs, thereby 
offering a potential source of cells with which to study interactions in the murine system. The 
establishment of the NFl knockout mouse strains (Jacks et aI . ,  1 994) allows for comparisons 
between normal cells and neurofibromin-deficient cells .  
We obtained conditioned media from Schwann cell cultures derived from wild-type, 
NFl +1-, and NFl -1- mice from the laboratory of Dr. Nancy Ratner (Department of Cell 
Biology, Neurobiology and Anatomy, College of Medicine, University of Cincinnati) .  We 
cultured bone marrow-derived mast cells in 1 0% concentrations of the various Schwann cell 
conditioned media and compared the cultures for differences in mast cell phenotype or rates 
of proliferation. Alcian blue/safranin stains were done to determine the percentage of cells 
containing safranin-positive (heparin-containing) granules, characteristic of the connective 
tissue mast cell phenotype (CTMC). Our laboratory has previously used the shifting of alcian 
blue/safranin staining to redder granulation as an indication of the presence of SCF in cell­
conditioned medium (Ryan, 1 992). Cultures containing each of the conditioned media were 
left untreated or were supplemented with either 50 ng/ml rmSCF, 50 U/ml rmIL-3 , or both. 
Cytospin preparations of the cells were stained with alcian blue and safranin, followed by 
microscopic examination. The total number of cells in five random 20X fields were counted, 
and the percentages of cells with san-anin-positive granules were calculated (Table I ) . Figure 
20 depicts the appearance of cells grown in the absence of any conditioned media, and is 
Table 1 .  Alcian blue/safranin staining of bone marrow-derived mast cells 
Percent cel1s containing safranin-positive granules 
no added 50 ng/ml 50 Vlml SCF + IL-3 
factors rmSCF rmIL-3 
Cells grown 
in cDMEM 0% 86% 0% 92% 
alone 
Cel1s grown in 10% conditioned media supplemented with 
50 U/ml rmIL-3 
Conditioned medium Safranin-positive cells 
cDMEM alone (no CM) 0% 
BALB/c 3T3 fibroblast CM 1 7% 
NFl +1+ Schwann cell eM 3 0% 
NFl +1- Schwann cell CM 20% 
NFl -1- Schwann cell CM 4% 
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Figure 20. Photomicrographs of alcian blue/safranin-stained bone marrow-derived mouse 
mast cells grown with rmSCF, rmIL-3, or both. Bone marrow-derived mouse mast cells were 
obtained as described in Materials and Methods. A1cian blue/safranin staining of cytospin 
preparations was done after 5 days of culture with (A) 50 ng/ml rmSCF, (B) 50 Vlml rmIL-3 ,  
or (C ) SCF + IL-3 . 
1 0 1  
1 02 
consistent with the results of previous studies in this laboratory. 
Cells grown in the presence of various conditioned media are represented in Figure 
2 I. An increase in the percentage of safranin-positive cells in CM-containing cultures given 
only IL-3 (Table 1 ), when compared to the absence of safranin staining in cultures which 
contain no conditioned media, suggests that the conditioned media contains one or more 
factors which contribute to the phenotypic shift. The results obtained with cultures containing 
BALB/c 3T3 fibroblast conditioned medium are similar to those from previous work in this 
laboratory (Jarboe et aI . ,  1 989) which led to the discovery of stem cell factor. 
Changes in the rate of proliferation of the mast cells were assessed based on 
incorporation of 3H-thymidine during DNA synthesis. After three days of culture in the 
different combinations of conditioned media and additives noted above, 1 !lCi oeH-thymidine 
was added to each well . After an additional 24 hours in culture, the amount of incorporation 
was determined using a scintillation counter (Figure 22). 
1 03 
Figure 2 1 .  Photomicrographs of alcian blue/safranin-stained bone marrow-derived mouse 
mast cells grown in Schwann cell-conditioned media from wild-type or NFl knockout mice. 
Alcian bluelsafranin stains were done on cytospin preparations of bone marrow-derived 
mouse mast cells grown for 5 days with 50 U/ml rmIL-3 in the presence of various cell 
culture-conditioned media. Shown are representative examples of cells grown in 1 0% 
BALB/c 3T3 fibroblast conditioned medium (A), or Schwann cell-conditioned medium from 
wild type (B), NFl +1- (C), or NFl -1- mice (D).  
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Figure 22. Proliferation of bone marrow-derived mouse mast cells grown in Schwann cell­
conditioned media from wild-type or NFl knockout mice. Bone marrow-derived mast cells 
were cultured for 3 days with cytokines and 1 0% concentrations of the conditioned media 
indicated. 1 IlCi oflH-thymidine was added to each well, and the plate was incubated for an 
additional 24 hours. Cells were harvested, and 3H-thymidine incorporation was determined 
using a scintillation counter. Data represent the mean ± SEM of triplicate wells .  
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Discussion 
The research described in this dissertation deals with some of the patterns of 
expression and biologic activities of stem cell factor. SCF is capable of acting on any cell 
which expresses its receptor, Kit. The Kit+ cells addressed in this dissertation research were 
mast cells and malignant schwannoma cell lines. Both Schwann cells and mast cells are found 
in high numbers in the neurofibroma nodules associated with NFl , and Schwann cells have 
been shown to make SCF. The hyperplastic Schwann cells in these lesions have an 
abnormally high tendency to become malignant. Many such solid tumors have been shown 
to involve an SCFIKit autocrine loop. Thus, neurofibromas and malignant schwannomas 
appear likely to have a complex dependency on the SCFlKit complex, whether in an autocrine 
or paracrine signalling pattern. This dissertation research investigates various aspects of SCF 
and Kit expression, with particular emphasis on which isoform of SCF might be expressed. 
To date, very few studies have attempted to make a distinction between different forms of 
SCF expression, membrane or soluble, and relate them to biologic or pathologic situations. 
Membrane-bound and soluble SCF clearly have different biologic activities. 
Membrane-bound SCF is more effective to induce proliferation and differentiation (Miyazawa 
et aI . ,  1 995) ,  whereas soluble SCF is more l ikely to be involved in chemotaxis of Kit+ cells 
(Blume-Jensen et al . ,  1 99 1 )  and augmentation of mediator release from mast cells (Columbo 
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et aI . ,  1 992; Wershil et aI . ,  1 992). Based on the previous work of John Ryan in this 
laboratory, we suspected that Schwann cell-derived SCF might play a role in the mast cell 
hyperplasia associated with NFl neurofibromas. However, it was not clear whether the S CF 
might be more likely to recruit mast cells, or cause mast cells to proliferate in situ, or both. 
Furthermore, we did not know what SCF isoform might be made by the Schwann cel ls .  
Before investigating soluble or membrane SCF effects on cells we suspected of 
expressing Kit only weakly, we first tested the effect of high concentrations of soluble SCF 
(recombinant) on strongly Kit+ cells, peritoneal mast cells . SCF and Kit have been implicated 
in  biologically relevant interactions involving adhesion, migration, survival, proliferation, 
differentiation, and activation (reviewed in Galli et aI . ,  1 994). We suspected that changes in 
expression of SCF and/or Kit resulting from a mutation of the NFl gene leads to the 
hyperproliferation of Schwann cells in a neurofibroma, perhaps partly due to recruitment of 
mast cel l s .  Therefore, we first wanted to demonstrate, in a more straight forward model 
system, stem cell factor-induced recruitment or proliferation of mast cells in vivo, so we 
injected high doses ofrmSCF169 into the peritoneal cavities of mice, and later examined them 
for site-specific mast cell hyperplasias. In addition, we compared the responses of otherwise 
healthy mice to those which had been infected with the intestinal helminth Nippostrongylus 
brasiliensis (Nb). It is known that Nb infection results in a mucosal mastocytosis (Befus and 
Bienenstock, 1 984), and has been used by this and other labs as a model system to study mast 
cell development. We expected that administration of rmSCFI69 would result in increased 
numbers of peritoneal mast cells, and further thought that the greater numbers of mast cells 
in the infected mice would lead to a more rapid clearance of the adult worms in the gut, 
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thereby suggesting that SCF might be acting as a therapeutic agent . 
Surprisingly, SCF treatment resulted in decreases in the number of mast cel ls  found 
in the peritoneal cavities of mice treated with rmSCF169, compared to control mice inj ected 
with phosphate-buffered saline (PBS) alone (Figure 1 ) .  The drop in peritoneal mast cell 
number in response to SCF treatment is similar to that previously observed with Nb infection 
(Huff et aI., 1 995). Kasugai and colleagues have also noted a loss of mast cell precursors in 
the b lood of mice infected with Nb (Kasugai et aI . ,  1 995) .  Our results are, however, in 
contrast to previous studies in which subcutaneous injections of recombinant SCF in mice led 
to the appearance of large numbers of mast cel ls at the dermal site of injection (Zsebo et aI . ,  
1 990b; Tsai e t  aI . ,  1 99 1 ) .  There was no  significant difference in the numbers of  mast cells i n  
back  dermis preparations of  control o r  SCF-treated mice (Figure 2), indicating that 
intraperitoneal injections of rmSCF169 do not seem to confer systemic effects. In addition, no 
significant differences in the degree ofNb infection were noted between PBS-treated controls 
and S CF-treated mice, in terms of the number of adult worms in the gut (Figure 4), or the 
daily expulsion of eggs in the feces (Figure 3) .  
To explain why the intraperitoneal administration of  high doses of rmSCF169 does  not 
lead to proliferation of mast cells, but rather reduction, we suggest that the mast cells could 
be activated and induced to degranulate, thereby rendering them undetectable by our methods .  
S CF has been shown to induce mediator release from purified human skin mast cells 
(Columbo et aI. ,  1 992) and from purified mouse peritoneal mast cells (Coleman et aI . ,  1 993)  
in vitro. This hypothesis is supported by our observations that SCF treatment combined with 
7 day Nb infection, which contributes both IgE plus antigen, resulted in lower numbers of 
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peritoneal mast cells than with either treatment alone, suggesting augmented degranulation. 
Alternatively, the lower numbers of mast cells detected in SCF-treated mice may reflect a 
change in the pattern of mast cell homing, as suggested by Kasugai and colleagues to be the 
mechanism of loss of mast cell progenitors from blood during Nb infection (Kasugai et aI , 
1 995). Further studies would be needed in this model system to test these hypotheses. We 
conclude from these experiments that the effects of high concentrations of soluble SCF are 
less predictable than previously thought. 
The major part of the dissertation research dealt with the possible etiologic role of the 
SCFlKit complex in NF l lesions. Although the manifestations of type I neurofibromatosis 
rarely lead to fatal consequences, NFl causes significant morbidity. In addition to the medical 
symptoms of the pain and mechanical limitations resulting from the size and location of 
neurofibromas, the patient must also deal with the unfortunate social stigma associated with 
being deformed. Developmental dysfunctions and learning disabilities occur more frequently 
in children and adolescents with NF 1 than in the general population (Dilts, 1 997), creating a 
tendency toward (or perhaps resulting from) a sense of low self esteem. Perhaps due to the 
low incidence of mortality associated with NF l ,  the degree of public awareness has not 
correlated well with the relatively high rate of occurrence of the disease. Although this may 
create obstacles in the way of gaining support for research efforts, it is not an indication of 
the relative importance of such research. The cloning of the NFl gene (Cawthon et ai , 1 990; 
Viskochil et ai , 1 990; Wallace et aI . ,  1 990) and the subsequent characterization of the gene 
product, neurofibromin, has greatly improved our understanding of the disease, and may 
possibly lead to the development of practical clinical interventions. However, even the NFl 
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gene cloning studies do not provide an adequate explanation for the overproliferation of 
S chwann cells and mast cells in the lesions. The purpose of this study has been to obtain 
information about some of the very basic mechanisms at work in NF I, specifically those 
involving stem cell factor and Kit interactions. 
We chose to focus on SCF and Kit due to a logical association of certain facts :  that 
mast cel ls (which express Kit and respond to SCF) are present in the nervous system 
associated with normal nerves (Bienenstock et aI . ,  1 99 1 ); that mast cells are increased at sites 
of nerve damage and repair (Isaacson, 1 976; Olsson, 1 97 1 )  or in nerve-associated tumors, 
such as neurofibromas and schwannomas (Isaacson, 1 976); and that Schwann cells produce 
stem cell factor (Ryan et a! . ,  1 994). We further sought to determine whether aberrations in 
the expression of either SCF (i .e. changes in isoform) or Kit (ectopic expression by Schwann 
cells) may be involved in the development of the tumors characteristic of NFl . 
Human stem cell factor exists as either a soluble or membrane-bound protein, resulting 
from alternative splicing and specific proteolysis (Anderson et a! . ,  1 99 1 ) . Each isoform is 
associated with distinctly significant biological activities (see discussion in Literature Review), 
which led us to the notion that a failure in SCF regulation resulting in aberrant expression of 
either form may contribute to pathology. Since we wanted to evaluate the relative expression 
of the two forms of SCF rnRNA, we developed techniques with which we could discriminate 
and quantitate them. Although a competitive RT-PCR protocol was effective at quantitating 
mRNA levels (Figure 5), we found that a ribonuclease protection assay (RPA) was better 
suited for sample-to-sample comparisons. Therefore, RP A was used throughout this study 
to detect SCF mRNA isoforms. 
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In early experiments using RNA extracted from human fibroblast-derived cell lines, 
we determined that we were able to detect either isoform of SCF mRNA by this method 
(Figure 7). However, in addition to the bands representing the protected fragments of 1 44 
nucleotides (membrane) and 222 nucleotides (soluble), we also noted additional bands 
indicating protected fragments of approximately 1 05 ,  1 75 ,  and 3 00 nucleotides. Since the 
radiolabeled transcript used as a probe in this protocol is  approximately 300 nucleotides long, 
the band of that size likely represents excess probe which remained unhybridized and 
undigested . By reducing the concentration of ribonucleases, and lowering the temperature 
of the digestion reaction, the 1 05 nucleotide fragment was eliminated, leaving the expected 
fragments, appearing as doublets, and the unexpected doublet around 1 75 nucleotides. 
Doublets such as these may result from transient strand separation at AU-rich regions of the 
RNA, allowing for RNase cleavage at that site, or they may represent non-specific cleavage 
due to secondary RNA structure. Similar unexpected fragments have been reported 
elsewhere (Huang et a! . ,  1 992; Kauma et a! . ,  1 996) .  
Having developed an RNase protection assay capable of detecting both SCF isoforms, 
we examined SCF isoform expression from malignant schwannoma cell lines and from 
neurofibroma tissues. The malignant schwannoma is a rare cancer of Schwann cell origin 
affecting much less than 1% of the general population (Cutler and Gross, 1 93 6) .  This rate 
of incidence is increased to up to 2% in NF I patients (Ponder, 1 990; Nimura, 1 992), which 
supports the notion that neurofibromin may function as a tumor suppressor (Weinberg, 1 99 1 ) .  
Because o f  the infrequency o f  occurrence of malignant schwannomas, cells and tissue samples 
from such tumors are in short supply, and are very difficult to obtain for research purposes. 
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We have, however, obtained four cell lines which have been derived from human malignant 
schwannomas, and have used them throughout this study in place of actual tumors or primary 
cultures of schwannoma-derived cells . We note here that cell lines are not completely 
accurate representations of the phenotypic characteristics of their in vivo cell counterparts, 
and interpretations of the data must be made with that in mind. We examined the stem cell 
factor mRNA expression of the malignant schwannoma cell lines by RP A. In every case, only 
the membrane-bound isoform was detected (Figure 9) . These findings were in contrast to 
results obtained with RNA from primary cultures of normal and keloid-derived human 
fibroblasts (Figure 8). The same pattern was observed in multiple subsequent experiments 
u sing the same or different RNA extractions. In view of the fact that, of the five human 
fibroblast cell lines used in the early RP A experiments (Figure 7), the two lines which 
expressed mRNA for the membrane-bound isoform of SCF grew much more rapidly than the 
other three which expressed the soluble isoform mRNA (Table 2), we wondered if the 
expression of primarily membrane-bound SCF correlated with the transformed phenotype of 
these cell lines. Therefore, we sought to determine if other SCF-expressing malignant cells 
exhibited a similar pattern of isoform expression. 
A panel of small cell lung carcinoma (SCLC) cell lines have been characterized with 
respect to stem cell factor expression (Krystal et aI . ,  1 996). We obtained RNA extracted 
from these, as well as from a breast cancer cell line, to address the question of a potential l ink 
between membrane-bound SCF expression and malignancy. The detection of only the soluble 
isoform of SCF mRNA in each of these samples (Figure 1 0) leads us to the conclusion that 
expression of the membrane-bound form is not required for a malignant phenotype in stem 
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Table 2. Patterns of stem cell factor and Kit expression and growth rates of cultured cells 
Cell lines SCF isoform Kit expression Rate of growth 
CCD I 8  soluble ND* slow 
Detroit 5 5 1  membrane ND rapid 
HS68 soluble ND slow 
HTl O80 soluble ND slow 
KEL-FIB membrane negative rapid 
MRC-9 soluble ND slow 
Primary fibroblasts soluble negative ND 
NF- I T  membrane positive rapid 
ST88- 1 4  membrane positive rapid 
STS-26T membrane positive rapid 
T265 membrane positive rapid 
*ND = not determined 
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cell factor-expressing cells .  However, these data do not rule out the possibility that any 
correlation between preferential expression of the membrane-bound isoform and malignancy 
(or perhaps simply hyperplasia) may be dependent upon the cell type. In other words, it may 
be true for Schwann cells, but not small cell lung carcinoma or breast cancer cells .  
The fact that these malignant schwannoma lines exclusively express the membrane 
isoform of SCF is striking in itself. A search of the literature does not reveal any other 
primary cell preparation or cell lines which exhibit such tight regulation toward the membrane 
SCF isoform. Thus, these malignant schwannoma lines may prove to be a good model system 
for studying how the alternative splicing of exon 6 of SCF is regulated. Majumdar and 
col leagues have studied SCF isoform regulation, but only in SCF transfectants, not in 
naturally occurring circumstances (Majumdar et aI . ,  1 996). 
To explore the possibility that all Schwann cell hyperplasias, not just Schwann cell 
malignancy, might be characterized by expression of the membrane-bound isoform of stem 
cell factor, we extracted RNA from tissues obtained by surgical excision of neurofibroma, 
vestibular schwannoma, acoustic neuroma, and meningioma tumors. Except for 
meningiomas, these all contain increased numbers of Schwann cells, but the Schwann cells are 
not transformed. Meningiomas were included as an example of a neural-associated tumor not 
involving Schwann cells. Ribonuclease protection assays performed on these samples indicate 
that the soluble isoform of stem cell  factor, but not the membrane-bound form, i s  being 
expressed in these tissues (Figures 1 2  and 1 3) .  As expected, the meningioma showed little 
SCF expression  of either isoform. It should not be assumed that the source of the SCF 
mRNA being detected in the other tumors is  exclusively Schwann cells, because the tumors 
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contain other SCF-producing cell types, including fibroblasts. The methods used here do not 
allow for the determination of the source of the mRNA from a mixed population of cel ls .  
Nevertheless, Schwann cells do represent a major cellular constituent of each of these lesions, 
and if there had been exclusive expression of membrane SCF, it would likely have been 
revealed by the RNase protection assay. 
In an earlier study in this laboratory, it was reported that the ST88- 1 4  human 
malignant schwannoma cell line expressed Kit, while normal human and neonatal rat Schwann 
cells did not (Ryan et al . ,  1 994). These findings, along with the detection of stem cell factor 
production by the same cells, were suggestive that the ST88- 14  cells might be responding to 
an autocrine growth loop. Coexpression of SCF and Kit has been reported in a variety of 
malignancies (Hibi et al . ,  1 99 1 ;  Toyota et al . ,  1 993 ; Inoue et al . ,  1 994; Hines et a! . ,  1 995), and 
transfection studies have provided strong evidence of a correlation between coexpression and 
growth factor independence in small cell lung carcinoma lines (Krystal et a! . ,  1 996). With the 
acquisition of three additional human malignant schwannoma cell lines, through related studies 
performed by Christopher Shelburne in this laboratory, we sought to determine if these also 
expressed Kit. Indirect immunofluorescence staining, using a monoclonal antibody directed 
against human Kit, was performed on the three cell lines, as well as the ST88- 1 4  line. The 
preparations were analyzed using a confocal laser cytometer, which revealed expression of 
Kit protein at low levels on all four malignant schwannoma lines (Figure 1 4) .  Additional 
characterizations, including immunoprecipitation of Kit protein from the cell lines, suggest 
that the protein may be truncated. Moreover, RT-PCR amplification and subsequent 
sequencing of fragments of the c-kit mRNA indicate a novel point mutation in the kinase 
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region of Kit which may lead to constitutive receptor activation (Shelburne et a! . ,  manuscript 
in  preparation). Taken together, these findings offer two possible explanations for the 
transformed phenotype of the malignant schwannoma cell lines : the cel ls are constantly 
induced to proliferate due to simultaneous expression of SCF and Kit, or they bear a mutation 
in Kit which causes it to be constitutively activated, leading to unregulated growth. 
As mentioned above, although the use of cell lines as a model system offers the 
advantages of abundance and availability, their phenotype may diverge from that of the 
corresponding cells in vivo. To further characterize the Schwann cells of malignant 
schwannomas as well as those of neurofibromas in situ, we obtained formalin-fixed, paraffin­
embedded sections of each tumor type and examined them for Kit expression. No primary 
cell cultures were available from these sources to perform experiments similar to those 
performed on the malignant schwannoma lines. As we have reported in the Results section, 
by performing immunohistochemical analyses of the sections, using a polyclonal antibody 
specific for Kit protein, we were able to detect abundant Kit expression by the resident mast 
cel ls (Figures 1 5 - 1 7) .  However, no Kit protein was detected on the Schwann cells by this 
method. We can not rule out the possibility that Kit may be expressed at levels too low to be 
detected by this method. Indeed, mature mast cells such as these are likely to express much 
higher numbers of Kit molecules than other cells (reviewed in Galli et aI . ,  1 994). We are 
currently developing techniques whereby we can adapt the immunohistochemistry protocol 
such that it can be analyzed with the highly sensitive confocal laser cytometer, thereby 
offering the same degree of sensitivity as was used with the malignant schwannoma cell lines. 
Production of substances with potential mitogenic effects has been observed in mast 
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cells (Pennington et aI . ,  1 9 9 1 )  and Schwann cells (Ridley et aI . ,  1 989;  Ohi et aI . ,  1 990). In 
addition, Schwann cells derived from a neurofibroma of an NF I patient appear to secrete 
growth factor activity which is not observed in Schwann cells from genetically normal 
individuals (Sheela et aI . ,  1 990). We have hypothesized that NFl Schwann cells produce 
factors (SCF and perhaps others) which are chemoattractive and mitogenic for mast cells .  
Thus, the mast cells might be drawn to the site where they, in turn, secrete growth factors to 
which the Schwann cells are responsive, resulting in the formation of a neurofibroma. Others 
have suggested similar theories concerning the involvement of mast cells in neurofibroma 
growth. Riccardi has suggested that mast cells may accumulate following local trauma, or in 
response to tropic factors, and that their secretions may induce abnormal proliferation in other 
cells due to the NFl mutation, resulting in neurofibroma growth (Riccardi, 1 990). 
To test whether human Schwann cells might up regulate the growth of human mast 
cells (such as might occur in NF I neurofibromas), we used malignant schwannoma lines and 
the HMC- I mast-like line, using both co-culture experiments and conditioned medium 
experiments. No upregulation ofHMC-1 growth or differentiation was observed. The slight 
decreases in HMC- I growth were likely due to slight nutritional deprivation due to dilution 
with spent (conditioned) medium. Also, since HMC- I cells have an activating Kit mutation 
(Furitsu et al . ,  1 993), any upregulation due to SCF might be hard to detect . In addition, the 
malignant schwannoma lines might not well represent Schwann cells from NFl neurofibromas. 
It would likely be informative to establish cocultures of human mast cel ls and Schwann 
cells derived from both genetically normal individuals and NF I patients, and monitor them for 
changes in phenotype. These changes might relate to maturation, differentiation, proliferation, 
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or activation. We are not aware of any studies of this sort to date, which is possibly an 
indication of the difficulties inherent in the derivation of pure cultures of human mast cells and 
Schwann cells. In an effort to circumvent these obstacles and approximate the conditions as 
closely as possible, we have performed preliminary experiments in the mouse system using 
conditioned media from NFl knockout Schwann cells kindly provided by Dr. Nancy Ratner 
at the University of Cincinnati .  We have cultured bone marrow-derived murine mast cells 
(BMMC) in the presence of mouse Schwann cell conditioned media (SCCM). Ihe sources 
of the SCCM include Schwann cells derived from wild-type, and NFl heterozygous (+/-) and 
homozygous (-/-) knockout mice. Changes in the phenotype or growth rate of the BMMC 
were then measured by alcian blue/safranin staining and tritiated thymidine incorporation, 
respectively. 
Alcian blue!sa/Tanin staining of mast cells has been used to differentiate between cells 
of the mucosal (MMC) or connective tissue (CIMC) phenotype. Ihe granules of CIMC 
contain heparin, which binds the safranin dye, resulting in pink or red staining. Stem cell 
factor is  produced by cells in the connective tissue microenvironment in vivo, and drives mast 
cell progenitors toward the CIMC phenotype, whereas the MMC result from the influence 
ofIL-3 in the mucosal microenvironment. In in vitro studies, a shift toward red granulation 
in  alcian blue!safranin stained mast cell cultures is an indication of the presence of SCF i n  the 
culture medium. A similar approach was used successfully by John Ryan in his dissertation 
research in  this lab to detect biologically active SCF in other mast cel l  co-cultures. In our 
experiments with Schwann cell-conditioned media (Figure 2 1 ), we noted that, in the presence 
ofIL-3 alone, SCCM from both NFl +/+ (wild type) and NFl +/- mice shifted the cultured 
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mast cells toward the CTMC phenotype as did cultures containing fibroblast-conditioned 
medium (FCM). In addition, we observed that the wild type SCCM induced a greater shift 
than did the +/- . However, NFl -/- SCCM appeared to have a diminished capacity to exert 
this  effect. It is possible that the Schwann cells of the homozygous knockout mice do not 
release soluble SCF into the medium (perhaps due to a change in isoform expression), and 
therefore do not drive the mast cells as effectively toward the CTMC phenotype. This 
possibility is particularly intriguing in view of the observation that the malignant schwannoma 
lines do not make soluble SCF (Figure I I ) .  The complete loss of neurofibromin in these cells 
may lead to the secretion of other cytokines which, in concert with exogenous SCF and IL-3 ,  
may co-stimulate the proliferation of the cultured mast cells .  Indeed, DNA synthesis was 
increased in mast cells grown in NFl -/- SCCM in the presence of both SCF and IL-3 
compared to all other culture conditions. A possible explanation for why NFl -/- Schwann 
cell-conditioned meduim augments growth but does not change phenotype is that whereas 
other cytokines in Schwann cell conditioned medium could l ikely augment mast cell growth 
(Figure 22), the ability to cause a change toward the connective tissue phenotype is a biologic 
activity that has been much more closely linked to SCF specifically. 
A possible explanation for the intermediate ability of NFl +/- Schwann cell­
conditioned medium to cause a shift in alcian blue/safranin staining is that a mutation  on a 
� NFl allele may cause a pru:ti.a! decrease in the production of soluble SCF by Schwann 
cells. Ifso, these cells might actually be models for Schwann cel ls in NFl , a genetic disease 
which is caused by an autosomal dominant mutation (heterozygous). On the other hand, 
when both alleles are non-productive, as is  certainly the case for both the mouse NFl 
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knockout Schwann cells and the ST88- 1 4  malignant schwannoma (Reynolds et aI . ,  1 992), 
soluble SCF bioactivity, as indicated by safranin-positive granules is  barely detectable (Table 
1) .  Studies involving the ST88- 1 4  malignant schwannoma line show that, although a single 
copy of the NFl gene appears to remain intact in these cells, NFl rnRNA expression was 
found by Northern analysis to be substantially reduced or absent (Reynolds et aI . ,  1 992) . 
Moreover, it has also been reported that ST88- 1 4  cells express extremely low levels of 
neurofibromin protein (DeClue et aI . ,  1 992) . It has been suggested that the greatly reduced 
NFl expression in this tumor cell may be due to a somatic mutation acquired by the intact 
allele, resulting in either greatly reduced transcription or message instability (Reynolds et aI . ,  
1 992). I t  is also possible that a homozygous mutation may lead to  the transformation of  the 
cell, as has been suggested for the ST88- 14 human malignant schwannoma (Reynolds et aI . ,  
1 992) .  Additional studies are required t o  determine i f  lack o f  soluble stem cell factor 
expression by Schwann cells might be caused by severe neurofibromin deficiency. 
The observation that only the membrane-bound form of SCF rnRNA is expressed by 
the four schwannoma cell lines implies that there may be a correlation between SCF isoform 
expression and control of Schwann cell proliferation. It is  interesting that faster rates of 
proliferation were observed in cultures of fibroblast cell lines which expressed the membrane­
bound isoform, compared to soluble SCF-producing cells (Table 2). Although no malignant 
schwan noma solid tumors were available for analysis by RP A, neurofibroma, vestibular 
schwannoma, and acoustic neuroma tumors, each of which is characteristically slow-growing 
and non-invasive, all expressed the soluble SCF isoform (Figures 1 2  and 1 3 ,  Table 3 ) .  In the 
future, it is hoped that, through collaborations with other laboratories, the experimental design 
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Table 3 .  Patterns of SCF and Kit expression by solid tumors 
Tumor SCF isoform Kit expression 
neurofibroma soluble negative 
malignant schwannoma ND* negative 
vestibular schwannoma soluble ND 
meningioma none detected ND 
acoustic neuroma soluble ND 
*ND = not determmed 
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can be expanded to include cultures of Schwann cells in mast cell-conditioned media, as well 
as cocultures of the two cell types from normal and knockout mice. 
In summary, the findings reported here indicate a significant involvement of stem cell 
factor and Kit in at least some of the pathological manifestations of NF l ,  perhaps in part 
through faulty regulation of SCF i soform expression. We first determined that high doses of 
recombinant stem cell factor may cause degranulation or rerouting of peritoneal mast cells, 
because their numbers are decreased in mice after repeated daily intraperitoneal injections of 
rmSCF169 In conjunction with Christopher Shelburne, we have found that four human 
malignant schwannoma cell lines all aberrantly express the Kit receptor, and that this protein 
may be truncated and constitutively activated. We further suggest that loss of neurofibromin 
function may have a direct effect on stem cell factor biologic activity, by regulating the 
induction toward a membrane isoform switch. There are two lines of evidence which suggest 
a possible role for neurofibromin in SCF isoform expression : the mouse NFl knockout data 
and the human ST88- 1 4  malignant schwannoma data, both of which lack neurofibromin 
activity and appear to express the membrane isoform of SCF. In fibroblasts, there appears 
to be a correlation of membrane SCF with more rapid rate of growth. A better understanding 
of the mechanisms by which expression of the stem cell factor isoforms i s  regulated is 
necessary to define a possible relationship between SCF expression and neurofibromin 
function. The malignant schwannoma cell lines and the NFl knockout mice likely represent 
good model systems in which these mechanisms can be studied. This information could lead 
to the development of therapeutic strategies for the treatment of the symptoms of NF I .  
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